Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements

Information

  • Patent Grant
  • 9433760
  • Patent Number
    9,433,760
  • Date Filed
    Tuesday, December 11, 2012
    11 years ago
  • Date Issued
    Tuesday, September 6, 2016
    7 years ago
Abstract
The disclosure pertains to an intravascular catheter for nerve modulation, comprising an elongate member having a proximal end and a distal end, a balloon having a lumen and a balloon wall, the balloon wall comprising RF permeable sections and non-electrically conductive sections, an electrode disposed within the balloon and extending distally to the furthest distal RF permeable section. The RF permeable sections may comprise a plurality of RF permeable windows, each window having a greater circumferential dimension than an axial dimension. The intravascular system is suited for modulation of renal nerves.
Description
FIELD

The invention generally pertains to percutaneous and intravascular devices for nerve modulation and/or ablation.


BACKGROUND

Certain treatments require the temporary or permanent interruption or modification of select nerve function. One example treatment is renal nerve ablation which is sometimes used to treat conditions related to congestive heart failure. The kidneys produce a sympathetic response to congestive heart failure, which, among other effects, increases the undesired retention of water and/or sodium. Ablating some of the nerves running to the kidneys may reduce or eliminate this sympathetic function, which may provide a corresponding reduction in the associated undesired symptoms.


Many body tissues such as nerves, including renal nerves, brain tissue, cardiac tissue and the tissue of other body organs are in close proximity to blood vessels or other body cavities and thus can be accessed percutaneously or intravascularly through the walls of the blood vessels. In some instances, it may be desirable to ablate perivascular nerves using a radio frequency (RF) electrode. In other instances, the perivascular nerves may be ablated by other means including application of thermal, ultrasonic, laser, microwave, and other related energy sources to the vessel wall.


In treatments involving perivascular nerves such as renal nerves, treatment methods employing such energy sources have tended to apply the energy as a generally circumferential ring to ensure that the nerves are modulated. However, such a treatment may result in thermal injury to the vessel wall near the electrode and other undesirable side effects such as, but not limited to, blood damage, clotting, weakened vessel wall, and/or protein fouling of the electrode.


SUMMARY

It is therefore desirable to provide for alternative systems and methods for tissue treatment such as intravascular nerve modulation treatments that distribute ablation or modulations sites along and around the vessel or other body cavity.


Some embodiments of the invention are directed to a balloon catheter configured for tissue modulation such as nerve modulation and/or ablation. The balloon catheter includes an inflatable balloon at or proximate a distal end of the device. The wall of the balloon is constructed so as to allow electricity such as RF energy through at certain locations and to prevent the transmission of RF energy or electricity at other locations. An electrode extends through the lumen of the balloon to supply the electricity or RF energy. In use, the balloon is inflated with a conductive fluid such as saline and positioned at a desired location for treatment. In some embodiments, the balloon may be in circumferential contact with a wall such as a blood vessel wall at the treatment location. The electrode is activated and the RF energy is transmitted through the conductive fluid and out the balloon through the RF permeable locations to modulate or ablate tissue.


The balloon may be a multilayer balloon with a first layer made from an RF permeable material and a second layer made from an electrically insulative material. The RF permeable material may be, for example, a hydrophilic polyurethane, and the electrically insulative material may be, for example, a (non-hydrophilic) polyurethane. The locations or windows that allow the transmission of RF energy do not include the electrically insulative material. These balloon walls of these RF permeable materials may be formed of a single layer of the RF permeable material and the remainder of the balloon may have two layers, one of the RF permeable material and one of the electrically insulative material.


The balloon catheter may include other elements such a multi-lumen catheter shaft. The multi-lumen catheter shaft may include a guidewire lumen and one or two fluid lumens as well as conductive members to connect the electrode and one or more sensors to a power and control system. For embodiments that include two fluid lumens, one fluid lumen may be used to introduce the conductive fluid into the balloon and the other fluid lumen may be used to evacuate the conductive fluid from the balloon. In this manner, the conductive fluid may be circulated within the balloon. In some embodiments, the fluid intake lumen has a fluid inlet fluidly connected to the balloon lumen at a distal location in the balloon and the fluid outlet lumen has a fluid outlet fluidly connected to the balloon lumen at a more proximal location in the balloon.


The electrode may be any suitable electrode member and may, for example, be a ribbon electrode that is helically wound about the catheter shaft within the balloon lumen and may be made from any suitable material such as platinum.


One illustrative embodiment has a balloon with three, four or more RF permeable windows through the balloon wall. The windows may be circular, oval, diamond-shaped, bowtie-shaped, or another appropriate shape and are spaced out longitudinally and circumferentially. Preferably, the windows are arranged so that the treatment area receives a tissue modulation or ablation treatment provides the desired coverage. For example, in some embodiments, the windows are arranged so that any line drawn longitudinally along the balloon wall passes through at least one window. Such a window arrangement allows for coverage around the circumference of the blood vessel while still permitting the windows to be spaced apart longitudinally. In other embodiments, one or more of the windows are arranged so that a line drawn longitudinally along the balloon wall passes through parts of two windows. In other embodiments, the number and arrangement of windows is such that so that any line drawn longitudinally along the balloon wall passes through at least two windows.


Another illustrative embodiment includes one or more helically shaped windows along the length, or along a portion of the length of the balloon. Another illustrative embodiment includes one or more windows that extend circumferentially around the balloon.


Another illustrative embodiment includes a helically shaped balloon where the balloon lumen is helically shaped and wraps around the catheter shaft. In this embodiment, one or more windows may be positioned on the outer diameter of the balloon catheter and are arranged so that any line drawn longitudinally (i.e. parallel to the catheter shaft) along the outer diameter of the balloon wall passes through at least one window. In one illustrative embodiment, a helically shaped window extends along the outer diameter of the helically shaped balloon.


In another illustrative embodiment, the RF permeable portions of the balloon are more compliant than the electrically insulative portions and pressure provided by the conductive fluid may cause the windows to bulge out. Such variations in the relative compliance of the different portions of the balloon may be effected by material selection, durometer selection, by varying the thickness of the layers or portions of layers or by other suitable method.


In another illustrative embodiment, the windows are molded to extend out from the balloon wall beyond the electrically insulative material.


In one illustrative method of use, a balloon catheter according to an embodiment of the invention is inserted percutaneously and/or intravascularly to a treatment location using a guidewire, a guide catheter or other conventional means. The balloon is inflated with the conductive fluid and the conductive fluid is circulated within the balloon. The electrode is activated and RF energy is transmitted from the electrode and through the conductive fluid and RF permeable windows into the tissue of the desired treatment area. The treatment may be ended after a predetermined time or after a predetermined condition is met. For example, impedance may be measured through the electrode and the treatment may be ended after a predetermined change in the measured impedance.


The above summary of some example embodiments is not intended to describe each disclosed embodiment or every implementation of the invention.





BRIEF DESCRIPTION OF DRAWINGS

The invention may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying drawings, in which:



FIG. 1 is a schematic view illustrating a renal nerve modulation system in situ.



FIG. 2 is a schematic view illustrating the distal end of a renal nerve modulation system.



FIG. 3 is a cross-sectional view of the renal nerve modulation system of FIG. 2.



FIG. 4 is another cross-sectional view of the renal nerve modulation system of FIG. 2.



FIG. 5 is a schematic view illustrating the renal nerve modulation system of FIG. 2 in situ.



FIG. 6 is a schematic view of a renal nerve modulation system.



FIG. 7 is a schematic view of a renal nerve modulation system.



FIG. 8 is a schematic view of a renal nerve modulation system.



FIG. 9 is a schematic view of a renal nerve modulation system.



FIG. 10a is a schematic view of a renal nerve modulation system.



FIG. 10b is a schematic view of the renal nerve modulation system of FIG. 10a.



FIGS. 11a-11d are projection views of the outer surface of example balloons of renal nerve modulation systems.





While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.


DETAILED DESCRIPTION

The following description should be read with reference to the drawings wherein like reference numerals indicate like elements throughout the several views. The drawings, which are not necessarily to scale, are not intended to limit the scope of the claimed invention. The detailed description and drawings illustrate example embodiments of the claimed invention.


All numbers are herein assumed to be modified by the term “about.” The recitation of numerical ranges by endpoints includes all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include the plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.


It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to effect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described unless cleared stated to the contrary.


While the devices and methods described herein are discussed relative to renal nerve modulation through a blood vessel wall, it is contemplated that the devices and methods may be used in other applications where nerve modulation and/or ablation are desired. The term modulation refers to ablation and other techniques that may alter the function of affected nerves and other tissue such as brain tissue or cardiac tissue. When multiple ablations are desirable, they may be performed sequentially by a single ablation device.



FIG. 1 is a schematic view of an illustrative renal nerve modulation system in situ. System 10 may include one or more conductive element(s) 16 for providing power to a renal ablation system including a renal nerve modulation device 12 disposed within a delivery sheath 14, which may be adapted to slidably contain the renal nerve modulation device 12 when the radially expanding region (not shown) of the elongate member is in a non-expanded configuration, the details of which can be better seen in subsequent figures. A proximal end of conductive element(s) 16 may be connected to a control and power element 18, which supplies necessary electrical energy to activate one or more electrodes to which the distal end of wire(s) 16 are attached at or near a distal end of the renal nerve modulation device 12. When suitably activated, the electrodes are capable of ablating tissue as described below. The terms electrode and electrodes may be considered to be equivalent to elements capable of ablating adjacent tissue in the disclosure which follows. Suitable materials for the delivery sheath 14, elongate member 12 and elements capable of ablating adjacent tissue are known in the art and in some embodiments may include internal and/or external layers of lubricious material(s). In some instances, return electrode patches 20 may be supplied on the legs or at another conventional location on the patient's body to complete the circuit. A proximal hub (not illustrated) having ports for a guidewire, an inflation lumen and a return lumen may also be included.


The control and power element 18 may include monitoring elements to monitor parameters such as power, temperature, voltage, pulse size, impedance and/or shape and other suitable parameters, with sensors mounted along renal nerve modulation device 12, as well as suitable controls for performing the desired procedure. In some embodiments, the power element 18 may control a radio frequency (RF) electrode. The electrode may be configured to operate at a frequency of approximately 460 kHz. It is contemplated that any desired frequency in the RF range may be used, for example, from 450-500 kHz. It is further contemplated that other ablation devices may be used as desired, for example, but not limited to resistance heating, ultrasound, microwave, and laser devices and these devices may require that power be supplied by the power element 18 in a different form.



FIG. 2 illustrates the distal portion of a renal nerve modulation device 12. Renal nerve modulation device 12 includes a balloon 22 and an electrode 24. When in use, the balloon is preferably filled with a conductive fluid 26 such as saline to allow the ablation energy to be transmitted from the electrode 24 through windows 28 that are permeable to RF radiation. Other appropriate conductive fluids include hypertonic solutions, contrast solution and mixtures of saline or hypertonic saline solutions with contrast solutions. The conductive fluid may be introduced through a fluid inlet 30 and evacuated through a fluid outlet 32, both in a central shaft 34. One or more sensors 50, such as thermocouple, may be included and may be disposed on the shaft 34, on the balloon 22 or at another suitable location.


A cross-sectional view of the shaft 34 of the renal nerve modulation device 12 proximal to the balloon is illustrated in FIG. 3. Shaft 34 may include a guidewire lumen 36, a lumen 38 connected to the fluid outlet 30, and a lumen 40 connected to the fluid inlet 32. The electrode 24, or a conductive element to supply power to the electrode may extend along the outer surface of the shaft or may be embedded within the shaft. The electrode 24 proximal to the balloon is preferably electrically insulated and is used to transmit power to the portion of the electrode disposed in the balloon. Conductors 42, two of which are illustrated in FIG. 3, may be used to supply power and to allow information to return from the one or more sensors 50. In some embodiments, the guidewire lumen and/or one of the fluid lumens 38, 40 may be omitted. In some embodiments, the guidewire lumen extends from the distal end of the device to a proximal hub. In other embodiments, the guidewire lumen can have a proximal opening that is distal the proximal portion of the system. In some embodiments, the fluid lumens 38, 40 can be connected to a system to circulate the fluid through the balloon 22 or to a system that supplies new fluid and collects the evacuated fluid. It can be appreciated that embodiments may function with merely a single fluid inlet lumen and a single fluid outlet into the balloon. It can also be appreciated that other lumen configurations are contemplated. For example, the three lumens may be disposed within each other or may be concentric. The guidewire lumen may be the innermost lumen and may be surrounded by the fluid inlet lumen which, in turn may be surrounded by the fluid outlet lumen. In another contemplated embodiment, only one of the fluid inlet and fluid outlet lumens is disposed around the guidewire lumen and the other of the fluid inlet and fluid outlet lumens extends parallel to and spaced apart from the guidewire lumen. Another contemplated embodiment lacks the fluid outlet lumen and the fluid inlet lumen is disposed around or concentrically around the guidewire lumen. In another contemplated embodiment, the guidewire lumen is omitted and the system includes only the fluid inlet lumen or only the fluid inlet and outlet lumens.


A cross-sectional view of the shaft 34 distal to fluid outlet 32 is illustrated in FIG. 4. The guidewire lumen 36 and the fluid inlet lumen 36 are present, as well as electrode 24. In the presently illustrated embodiment, conductors 42, which are connected to one or more sensors 50, are not present in this cross-sectional view. It can be appreciated that in embodiments that have one or more distal sensors, one or more conductors 42 may be present to connect with then.


Balloon 22 is shown in cross-section as having a first layer 44 and a second layer 46. A window 28 is formed in balloon 22 by the absence of second layer 46. First layer 44 is preferably made from an RF permeable material. One suitable material is a hydrophilic polyurethane. Other suitable materials include other hydrophilic polymers such as hydrophilic Pebax, hydrophilic nylons, hydrophilic polyesters, or block co-polymers with built-in hydrophilic blocks. Hydrophilic Pebax grades that may be suitable include Pebax MV1074, Pebax MV 1041, Pebax MP 1878, Pebax MV-3000, and Pebax MH-1657. In some embodiments, one ore more of the hydrophilic polymers such as the hydrophilic Pebax grades are used in blends with other polymers used in balloons such as Pebax 6333, Pebax 7033, Pebax 7233, Nylon 12, Vestamid L2101F, Grilamid L20, and Grilamid L25. Suitable hydrophilic polymers may exhibit between 6% to 120% hydrophilicity (or % water absorption), between 20% to 50% hydrophilicity or other suitable range. The second layer 46 is preferably made from an electrically non-conductive polymer such as a non-hydrophilic polyurethane, Pebax, nylon, polyester or block-copolymer. Other suitable materials include any of a range of electrically non-conductive polymers. The materials of the first layer and the second layer may be selected to have good bonding characteristics between the two layers. For example, a balloon 22 may be formed from a first layer 44 made from a hydrophilic Pebax and a second layer 46 made from a regular or non-hydrophilic Pebax. In other embodiments, a suitable tie layer (not illustrated) may be provided between the two layers.



FIG. 5 illustrates the distal end of device 12 in situ. Preferably, the device 12 is available in various sizes, and a size is selected that will allow the windows 28 of the balloon 22 to contact the wall of a blood vessel 48. The balloon is preferably somewhat compliant so that a balloon having a nominal 4 mm diameter can be expanded to fit a blood vessel of between 3.5 mm and 5 mm.


The particular balloon illustrated in FIG. 5 may be suitable for use in a renal nerve modulation application. Renal nerve extends generally longitudinally around the outside of a renal artery. This means that one can vary the longitudinal position of any particular circumferential treatment and achieve the same nerve modulation effect. Thus windows 28 are arranged to achieve complete circumferential coverage of the blood vessel while spaced apart longitudinally. In this particular case, the four windows 28 each cover a different 90 degree arc of the blood vessel. Each window may cover more than a 90 degree arc. For example, the windows 28 may cover a 100 or 110 degree arc to allow for some overlapping coverage of the windows 28. Windows 28 of this embodiment are four in number and generally circular in shape. It can be appreciated that variations in the number of windows and the shape of the windows are contemplated. For example, embodiments are contemplated which include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more windows and which include windows that are circular, oval, rectangular, or polygonal. Moreover, the windows having a different length and width may be oriented so that the largest dimension is parallel to the longitudinal axis, perpendicular to the longitudinal axis or at another angle with respect to the longitudinal axis such as a 45 degree angle. In some embodiments, each window may have an aspect ratio of 2:1, 3:1 or 4:1, where the major dimension is perpendicular to the longitudinal axis of the balloon. In some embodiments, the window or windows may have a custom pattern to provide a particular treatment pattern.


Electrode 24 may be a flat ribbon electrode made from platinum, gold, stainless steel, cobalt alloys, or other non-oxidizing materials. In some instances, titanium, tantalum, or tungsten may be used. Electrode 24 may extend along substantially the whole length of the balloon 22 or may extend only as far as the distal edge of the most distal window 28. The electrode 24 may have a generally helical shape and may be wrapped around shaft 34. In some cases, electrode 24 may be bonded to shaft 34. The electrode 24 and windows 28 may be arranged so that the electrode extends directly under the windows 28. In some embodiments, electrode 24 may be a wire or may be a tubular member disposed around shaft 34. In some embodiments, a plurality of electrodes 24 may be used and each of the plurality may be fixed to the shaft 34 under windows 28 and may share a common connected to conductive element 16. In other embodiments that include more than one electrode, each electrode may be separately controllable. In such embodiments, the balloon may be partitioned into more than one chamber and each chamber may include one or more electrodes. The electrode may be selected to provide a particular level of flexibility to the balloon to enhance the maneuverability of the system. It can be appreciated that there are many variations contemplated for electrode 24.



FIG. 6 illustrates the distal portion of another renal nerve modulation device 12 that is similar to the device 12 of FIG. 2 except as described herein. The renal nerve modulation device 12 of FIG. 6 includes previously described elements such as the shaft 34, the multi-layer balloon 22 and the electrode 24. Rather than a plurality of windows 28 as illustrated in the FIG. 2 embodiment, this embodiment has a single helical window 28. Helical window 28 may wrap around the balloon 22 for at least one full turn, or for 2, 3, 4, 5 or more turns as illustrated. Some embodiments include two or more helical windows 28 spaced apart from each other and winding around the balloon 22 at the same pitch.


Another variation is illustrated in FIG. 7, in which, rather than the plurality of balloons 28 illustrated in the FIG. 2 embodiment, this embodiment has a single balloon 28 that extends circumferentially around the middle portion of balloon 22. Two, three or more like windows 28 may be included in other contemplated variations of this embodiment. In one contemplated variation, the entire balloon wall is permeable to RF energy. Such an embodiment may have a balloon that includes a layer 44 and does not have a layer 46.



FIG. 8 illustrates the distal portion of another renal nerve modulation device 12 that is similar to the device 12 of FIG. 2 except as described herein. The renal nerve modulation device 12 of FIG. 7 includes previously described elements such as the shaft 34, the multi-layer balloon 22 and the electrode 24 (not illustrated). Balloon 22 of this embodiment is helically shaped and is wrapped around shaft 34. A window 28 is helically shaped and follows the outer diameter of the spiral. A variation of this embodiment is illustrated in FIG. 9 in which windows 28 are disposed periodically along the outer diameter of the spiral balloon 22. The windows are preferably arranged to provide complete circumferential coverage while being spaced longitudinally. The number and shape of the windows 28 may be varied as desired.



FIGS. 10a and 10b illustrate the distal portion of another renal nerve modulation device 12 that is similar to the device 12 of FIG. 2 except as described herein. FIG. 10a illustrates the device 12 expanded with nominal pressure and FIG. 10b illustrates the device 12 expanded with higher pressure. The higher pressure allows the windows 28 to expand out beyond the outer surface of the second layer 46 of the balloon. In this manner, a particular size of device 12 of FIGS. 10a and 10b may be suitable for use with a wider range of sizes of blood vessels. Device 12 may be made in a variety of ways. It can be appreciated, with reference to FIG. 4, that windows 28 may be thinner than the other portions of balloon 22. A thinner layer of a compliant polymer such as the hydrophilic polyurethane may be more readily expanded than the double layer of material present in the rest of the balloon. This effect may be enhanced by using a less compliant material for the second layer 46 of the balloon 22 or by increasing the thickness of the second layer 46. Suitable materials may include a less-compliant polyurethane (different durometers 85A to 55D), a nylon or a polyethylene terephthalate (PET) or any suitable electrically non-conductive polymer.


In a variation of the embodiment of FIG. 10b, the balloon may be molded or heat-treated so that windows 28 are shaped to be concave as illustrated in this figure under nominal pressure. In such an embodiment, the windows may contact the vessel wall under lower pressure and the balloon would be expandable to different diameters by the application of different amounts of pressure.



FIGS. 11a-11d illustrate projections of the cylindrical central portion of a balloon wall (i.e. the figure illustrates the cylindrical central portion of the balloon wall as if it were cut open and laid flat). The balloon wall of these figures may be readily incorporated into any of the nerve modulation systems described herein. Balloon 22 includes a plurality of windows 28 defined by an absence of electrically insulative layer 44. The windows are arranged on the balloon such that their greatest dimension extends circumferentially (i.e. along a circumference of the cylindrical balloon wall) and their narrowest dimension extends axially (i.e. in the direction of the central longitudinal axis of the balloon 22). The windows 28 are arranged such that any line drawn from the proximal end of the cylindrical balloon wall to the distal end of the cylindrical balloon wall passes through at least one balloon.


The windows may overlap circumferentially while being spaced apart axially. If a line drawn from the proximal end of the cylindrical balloon wall to the distal end of the cylindrical balloon wall passes through two balloons, those two balloons are said to circumferentially overlap.


The degree of circumferential overlap may be expressed in terms of the circumferential dimension of a window 28, in terms of the circumference of the balloon or in terms of an absolute dimension. For example, two adjacent windows may exhibit circumferential overlap that is between 0.2 and 0.8 mm, that is between 0.3 and 0.7 mm, that is between 0.4 and 0.6 mm, that is at least 0.3 mm, that is at least 0.4 mm, or that is at least 0.5 mm, or that is between 20% and 30% of the circumferential dimension of one of the two windows, that is between 24% and 26% of the circumferential dimension of one of the two windows, that is between 5% and 15% of a circumferential dimension of the cylindrical balloon wall, that is between 6% and 7% of a circumferential dimension of the cylindrical balloon wall, or that is between 10% and 14% of a circumferential dimension of the cylindrical balloon wall, for example.


The windows 28 preferably have a greater circumferential dimension than axial dimension. For example, the ratio of axial dimension to circumferential dimension for a window may be greater than 1.5:1, greater than 2:1, greater than 3 to 1 or some other suitable number. A window may have an axial dimension of 1 mm, 1.25 mm, 1.5 mm, 1.75 mm, 2 mm, 2.25 mm, 2.5 mm or other suitable dimension and a circumferential dimension of greater than 3 mm such as 3 mm, 3.5 mm, 4 mm, 4.5 mm or 5 mm. The circumferential dimension of a window 28 may be 20%, 25%, 30% or other suitable percentage of the circumferences of the cylindrical portion of the balloon wall.


The windows 28 of FIGS. 11a and 11b are shown as being arranged in a generally helical manner in that each adjacent window is offset axially and circumferentially (while overlapping circumferentially) from the previous window. Any number of windows sufficient to provide complete circumferential coverage may be used. In the embodiment of FIG. 11a, five windows 28 are illustrated. Some embodiments may be include 3, 4, 5, 6, 7, 8, 9, 10 or more windows and, if arranged helically as illustrated in FIG. 6, may extend for more than one turn around the balloon wall. It will be appreciated that a helical configuration is not necessary to provide complete circumferential coverage. Complete circumferential coverage means that the windows are arranged such that any line drawn from the proximal end of the cylindrical balloon wall to the distal end of the cylindrical balloon wall passes through at least one balloon.


The windows of FIG. 11a are illustrated as oblong. FIGS. 11b-11d illustrate other suitable window shapes such as oval (FIG. 11b), bowtie (FIG. 11c) and diamond (FIG. 11d).



FIGS. 11c and 11d illustrate balloon patterns where more than one window 28 located along the same circumference such that windows are in a grid pattern. The windows may be thought to be located on each of the intersections of an imaginary grid where the lines of the grid are circumferential lines on the cylindrical balloon wall and helically lines extending from a proximal end to a distal end of the cylindrical balloon wall. The grid lines may be spaced at regular intervals or at irregular intervals. The grid may include two circumferential and two helical lines and thus provide four intersections at which windows are located. The grid may include three circumferential and two helical lines and thus provide six intersections at which windows are located. The grid may include four circumferential and two helical lines and thus provide eight intersections at which windows are located. The grid may include five circumferential and two helical lines and thus provide ten intersections at which windows are located (as illustrated in FIGS. 11c and 11d). The grid may include two circumferential and three helical lines and thus provide six intersections at which windows are located. The grid may include three circumferential and three helical lines and thus provide nine intersections at which windows are located. The grid may include four circumferential and three helical lines and thus provide twelve intersections at which windows are located. Or the grid may be includes any desired number of circumferential and helical lines in any regular or irregular pattern so long as the windows provide complete circumferential coverage. It can be appreciated that significant circumferential overlap is created by such a grid pattern of windows. As the windows correspond to the sites on the vessel wall where the ablation treatment is provided, such circumferential overlap helps to ensure complete circumferential treatment of a vessel wall.


Multilayer balloons 22 having windows 28 may be made according to one of the methods described herein or by another suitable method. In one method, the first layer 44 and the second layer 46 of the balloon are manufactured separately, using blow-molding techniques or other suitable methods. Holes are formed in second layer 46 by a laser, hole punch, mechanical or hydraulic cutting element or other suitable technique. The first layer 44 is positioned inside of the second layer 46 and the two layers 44, 46 are fused together using heat, a chemical solvent, an adhesive or other suitable technique. In some cases, the two layers may be positioned inside of a mold and/or pressure may be exerted inside layer 44 to fuse the two layers in an expanded position using heat, solvents or adhesives. In some instances, the two layers are not directly joined but rather are separately attached to shaft 34.


In another method of manufacture, the inner layer 44 is formed over a flexible mandrel. The flexible mandrel has a shape like that of inner layer 44 in the expanded position but is made from a material, such as silicon, that does not adhere well to the material of the inner layer 44. The inner layer 44 may be formed over the flexible mandrel by dip coating, spray coating, blow molding or other suitable techniques. A masking material is applied over the inner layer where the one or more windows 28 are desired. The masking material may be fixed to the inner layer using a removable or temporary adhesive. The flexible mandrel, with the inner layer and masking material thereon is then dip coated again using a non-conductive polymer to form outer layer 46. The outer layer is cut at the edges of the masking material and the masking material along with the outer layer material that is on the masking material is removed, thus forming balloon 22. Finally, the flexible mandrel is removed from within balloon 22.


The helical balloons of the FIG. 8 and FIG. 9 embodiments may be formed from a balloon precursor that has two lumens side by side. The first lumen is the balloon lumen and the second lumen fits over shaft 34. This balloon precursor is formed into a dual layer balloon having windows 28 as discussed above. A straight mandrel is then inserted into the second lumen and the balloon precursor is twisted around the straight mandrel to form the first lumen into a helical shape. The second lumen may be inflated and the twisted balloon precursor is heat set into the helical shape. In some variations, the twisted balloon precursor is inserted into a helical mold and heat set in the helical mold to help for the helical balloon shape. The straight mandrel is then removed from the first lumen and the then helical balloon 22 is joined to a shaft.


In use, a renal ablation system such as system 12 is provided. The system may be used with a standard guide catheter such as a 6 French guide catheter. The balloon and in particular the hydrophilic or techophilic material may be hydrated as part of the preparatory steps. Hydration may be effected by soaking the balloon in a saline solution. A one minute, five minute or other suitable soak may be effect. Then the system 12 may be introduced percutaneously as is conventional in the intravascular medical device arts by using a guide catheter and/or a guide wire. For example, a guide wire such as a 0.014″ diameter guidewire may be introduced percutaneously through a femoral artery and navigated to a renal artery using standard radiographic techniques. In some embodiments, a delivery sheath 14 may be introduced over the guide wire and the guide wire may be withdrawn, and the system 12 may be then introduced through the delivery sheath. In other embodiments, the system 12 may be introduced over the guidewire, or the system, including a delivery sheath 14 may be introduced over a guidewire. In embodiments involved a delivery sheath 14, the system 12 may be delivered distally from the distal end of the delivery sheath 14 into position, or the delivery sheath may be withdrawn proximally to expose the system 12. A conductive fluid 26 is introduced into the balloon through fluid inlet lumen 40 and fluid inlet 30. The conductive fluid expands the balloon to the desired size. The balloon expansion may be monitored indirectly by monitoring the volume of conductive fluid introduced into the system or may be monitored through radiographic or other conventional means. Optionally, once the balloon is expanded to the desired size, fluid may be circulated within the balloon by continuing to introduced fluid through the fluid inlet 30 while withdrawing fluid from the balloon through the fluid outlet 32. The rate of circulation of the fluid may be between 2 and 20 ml/min, between 3 and 15 ml/min, between 5 and 10 ml/min or other desired rate of circulation. The balloon may be kept at or near a desired pressure such as a pressure of between 1 and 6 atmospheres, between 1.5 and 4 atmospheres, between 2.5 and 3.5 atmospheres or other desired pressure. The electrode 24 is then activated by supplying energy to the electrode. The energy may be supplied at 400-500 Hz and at between 0.5 and 1 amp. The energy is transmitted through the medium of the conductive fluid and through windows 28 to the blood vessel wall to modulate or ablate the tissue. The second layer 46 of the balloon prevents the energy transmission through the balloon wall except at windows 28 (which lack second layer 46). The progress of the treatment may be monitored by monitoring changes in impedance through the electrode. Other measurements such as pressure and/or temperature measurements may be conducted during the procedure as desired. The circulation of the conductive fluid 26 may mitigate the temperature rise of the tissue of the blood vessel 48 in contact with the windows 28. The electrode 24 is preferably activated for an effective length of time, such as 1 minute or 2 minutes. One the procedure is finished at a particular location, the balloon 22 may be partially or wholly deflated and moved to a different location such as the other renal artery, and the procedure may be repeated at another location as desired using conventional delivery and repositioning techniques.


EXAMPLES

While various embodiments of the nerve modulation system have been described with respect to the drawings, several embodiments will now be described using claim language. However, the following examples are not intended to be inclusive of every embodiment or combination of features described herein.


1. An intravascular catheter, comprising:


an elongate member having a proximal end and a distal end;


a balloon having an interior surface, and exterior surface, a lumen defined by the interior surface and comprising at least one section that is permeable to RF radiation, the at least one section extending from the interior surface of the balloon to the exterior surface of the balloon; and


an electrode disposed in the balloon.


2. The intravascular catheter of example 1 wherein the balloon further comprises at least one section that is non-electrically conductive.


3. The intravascular catheter of any of examples 1-2 wherein the balloon comprises three or more sections that are permeable to RF radiation.


4. The intravascular catheter of example 3 wherein the three or more sections are spaced circumferentially and longitudinally with respect to each other.


5. The intravascular catheter of any of examples 3-4 wherein the balloon comprises four sections that are permeable to RF radiation.


6. The intravascular catheter of example 1 wherein the at least one section is a helically shaped section.


7. The intravascular catheter of example 1 wherein the at least one section is a cylindrical section extending around the circumference of the balloon.


8. The intravascular catheter of example 7 wherein the at least one section is situated centrally on the balloon between a proximal end of the balloon and a distal end of the balloon.


9. The intravascular catheter of any of examples 1-2 wherein the balloon has a helically-shaped lumen.


10. The intravascular catheter of example 9 wherein the at least one section is helically shaped and extends along the outer diameter of the balloon.


11. The intravascular system of example 9 wherein the balloon comprises three or more sections that are permeable to RF radiation.


12. The intravascular system of example 11 wherein the three or more sections are spaced circumferentially and longitudinally with respect to each other.


13. The intravascular system of any of examples 11-12 wherein the balloon comprises four sections that are permeable to RF radiation.


14. The intravascular catheter of any of examples 9-13 wherein the sections are located on the outer diameter of the spiral.


15. The intravascular catheter of any of examples 2-14 wherein the at least one RF permeable section comprises a compliant polymeric material.


16. The intravascular catheter of example 15 wherein the non-electrically conductive section comprises a non-compliant polymeric material.


17. The intravascular catheter of any of examples 1-16 wherein the at least one RF permeable section comprises a hydrophilic polymer.


18. The intravascular catheter of example 17 wherein the at least one RF permeable section comprises a hydrophilic polyurethane.


19. The catheter of any of examples 1-18 wherein the at least one RF permeable section comprises a hydrophilic polymer selected from the group consisting of hydrophilic Pebax, hydrophilic nylons, hydrophilic polyesters, or block co-polymers with built-in hydrophilic blocks, Pebax MV1074, Pebax MV 1041, Pebax MP 1878, Pebax MV-3000, Pebax MH-1657.


20. The catheter of any of examples 17-19 wherein the at least one RF permeable section comprises the hydrophilic polymer blended with a second polymer.


21. The catheter of example 20 wherein the second polymer is selected from a group consisting of Pebax 6333, Pebax 7033, Pebax 7233, Nylon 12, Vestamid L2101F, Grilamid L20, and Grilamid L25.


22. The catheter of any of examples 17-21 wherein the hydrophilic polymer has between 20% to 50% hydrophilicity.


23. The catheter of any of examples 2-22 wherein the non-electrically conductive section comprises a non-hydrophilic polymer.


24. The intravascular catheter of any of examples 2-23 wherein the non-electrically conductive section comprises a non-hydrophilic polyurethane.


25. The intravascular catheter of any of examples 1-24 wherein the balloon comprises a first layer and a second layer.


26. The intravascular catheter of example 25 wherein the first layer is permeable to RF radiation and the second layer is non-electrically conductive.


27. The intravascular catheter of any of examples 25-26 wherein the first layer is inside the second layer.


28. The intravascular catheter of any of examples 25-27 wherein the at least one section that is permeable to RF radiation does not include the second layer.


29. The intravascular catheter of any of examples 25-28 wherein the at least one section that is permeable to RF radiation consists essentially of the first layer.


30. The intravascular catheter of any of examples 25-29 wherein at the at least one section that is permeable to RF radiation, the first layer defines the outer surface of the balloon.


31. The intravascular catheter of example 25 wherein the first layer is permeable to RF radiation and the second layer is non-electrically conductive, wherein the first layer is generally inside the second layer, wherein at the at least one section that is permeable to RF radiation, the first layer defines the outer surface of the balloon, and wherein at the at least one section that is permeable to RF radiation, the first layer extends radially beyond the second layer.


32. The intravascular catheter of example 31 wherein the at least one section that is permeable to RF radiation comprises a plurality of convex windows.


33. The intravascular catheter of any of examples 1-32 wherein the electrode extends under at least one section that is permeable to RF.


34. The intravascular catheter of any of examples 1-32 wherein the electrode extends for at least 80% the length of the balloon.


35. The intravascular catheter of any of examples 1-34 wherein the electrode is helically shaped.


36. The intravascular catheter of any of examples 1-35 wherein the elongate member extends the length of the balloon.


37. The intravascular catheter of example 36 wherein the electrode is disposed on an outer surface of the elongate member.


38. The intravascular catheter of any of examples 36-37 wherein the elongate member comprises a guidewire lumen having an open distal end.


39. The intravascular catheter of any of examples 36-38 wherein the elongate member further comprises a fluid supply lumen having an opening fluidly connected to the balloon lumen.


40. The intravascular catheter of example 39 wherein the elongate member further comprises a fluid return lumen having an opening fluidly connected to the shaft.


41. The intravascular catheter of example 40 wherein the fluid supply lumen opening is distal the fluid return lumen opening.


42. The intravascular catheter of example 41 wherein the fluid supply lumen opening is in a distal waist of the balloon.


43. The intravascular catheter of example 42 wherein the fluid return lumen opening is in a proximal waist of the balloon.


44. The intravascular catheter of any of examples 1-43 further comprising a temperature sensor.


45. The intravascular catheter of example 44 wherein the temperature sensor is disposed on the elongate member.


46. The intravascular catheter of example 44 wherein the temperature sensor is disposed on the balloon.


47. An intravascular catheter, comprising:


an elongate member having a proximal end and a distal end;


a balloon having a lumen and a balloon wall, the balloon wall comprising one or more RF permeable windows through a non-electrically conductive balloon wall, the one ore move RF permeable windows impervious to fluid flow;


an electrode disposed within the balloon and extending distally to the furthest distal RF permeable section.


48. The intravascular catheter of example 47, wherein the electrode is helically shaped.


49. The intravascular catheter of any of examples 47-48 wherein the elongate member extends through the balloon.


50. The intravascular catheter of example 49 further comprising a fluid supply lumen and fluid return lumen fluidly connected to the balloon lumen.


51. An intravascular catheter, comprising:


an elongate member having a proximal end and a distal end;


a balloon having an interior surface, an exterior surface, a lumen defined by the interior surface and a cylindrical wall extending between the interior surface and the exterior surface, the cylindrical wall having a proximal end and a distal end, the balloon having a plurality of electrically conductive windows disposed in the wall and able to pass an electric current between the interior surface and the exterior surface, the plurality of windows arranged such that every line extending along the wall the shortest distance from the proximal end of the wall to the distal end of the wall passes through at least one window, wherein at least one of the plurality of windows extends further in a circumferential direction than in an axial direction and wherein the balloon wall is otherwise electrically insulative; and


an electrode disposed in the balloon.


52. The catheter of example 51 wherein at least one of the plurality of windows is oval.


53. The catheter of example 51 wherein at least one of the plurality of windows is oblong.


54. The catheter of example 51 wherein at least one of the plurality of windows is diamond-shaped.


55. The catheter of example 51 wherein at least one of the plurality of windows is bowtie-shaped.


56. The catheter of any of examples 51-55 wherein the plurality of windows are spaced axially from each other.


57. The catheter of any of examples 51-56 wherein the plurality of windows are arranged in a spiral shape on the balloon wall.


58. The catheter of any of examples 51-57 wherein any two adjacent windows circumferentially overlap such that a line extending along the wall the shortest distance from the proximal end of the wall to the distal end of the wall passes through the two adjacent windows.


59. The catheter of example 58 wherein any two adjacent windows have a circumferential overlap of at least 0.3 mm.


60. The catheter of example 58 wherein any two adjacent windows have a circumferential overlap of at least 0.4 mm.


61. The catheter of example 58 wherein any two adjacent windows have a circumferential overlap of at least 0.5 mm.


62. The catheter of any of examples 58-61 wherein any two adjacent windows have a circumferential overlap of between 20% and 30% of the circumferential dimension of one of the two adjacent windows.


63. The catheter of any of examples 58-62 wherein any two adjacent windows have a circumferential overlap of between 24% and 26% of the circumferential dimension of one of the two adjacent windows.


64. The catheter of any of examples 58-63 wherein any two adjacent windows have a circumferential overlap of between 6% and 7% of a circumferential dimension of the cylindrical balloon wall.


65. The catheter of any of examples 58-63 wherein any two adjacent windows have a circumferential overlap of between 10% and 14% of a circumferential dimension of the cylindrical balloon wall.


66. The catheter of any of examples 51-65 wherein the ratio of the circumferential dimension to the axial dimension of at least one of the plurality of windows is between 1.5:1 and 4:1.


67. The catheter of any of examples 51-65 wherein the ratio of the circumferential dimension to the axial dimension of at least one of the plurality of windows is 1.5:1.


68. The catheter of any of examples 1-65 wherein the ratio of the circumferential dimension to the axial dimension of at least one of the plurality of windows is about 2:1 and 4:1.


69. The catheter of any of examples 1-65 wherein the ratio of the circumferential dimension to the axial dimension of at least one of the plurality of windows is about 3:1.


70. The catheter of any of examples 1-69 wherein the ratio of the circumferential dimension to the axial dimension is the same for each of the plurality of windows.


71. The catheter of any of examples 1-70 wherein each of the plurality of windows is the same shape.


72. The catheter of any of examples 1-71 wherein the plurality of windows comprises four windows.


73. The catheter of any of examples 1-72 wherein the plurality of windows comprises six windows.


74. The catheter of any of examples 1-73 wherein the plurality of windows comprises eight windows.


75. The catheter of any of examples 1-74 wherein the plurality of balloons are arranged on the intersections of a grid wherein the grid lines are a plurality of circumferential lines of the balloon wall and a plurality of helical lines extending from the proximal end of the balloon wall to the distal end of the balloon wall.


76. The catheter of example 75 wherein the plurality of helical lines are equally spaced around the balloon walls.


77. The catheter of any of examples 75-76 wherein the plurality of helical lines consist of two helical lines.


78. The catheter of any of examples 75-76 wherein the plurality of helical lines consist of three helical lines.


79. The catheter of any of examples 75-76 wherein the plurality of helical lines consist of four helical lines.


80. The catheter of any of examples 75-79 wherein the plurality of circumferential lines are spaced at regular intervals.


81. The catheter of any of examples 75-80 wherein the plurality of circumferential lines consist of two circumferential lines.


82. The catheter of any of examples 75-80 wherein the plurality of circumferential lines consist of three circumferential lines.


83. The catheter of any of examples 75-80 wherein the plurality of circumferential lines consist of four circumferential lines.


84. The catheter of any of examples 51-83 wherein a circumferential dimension of at least one of the plurality of balloons is between 20% and 30% of the circumference of the cylindrical balloon wall.


85. The catheter of any of examples 51-84 wherein a circumferential dimension of at least one of the plurality of balloons is between 22% and 28% of the circumference of the cylindrical balloon wall.


86. The catheter of any of examples 51-85 wherein a circumferential dimension of at least one of the plurality of balloons is between 24% and 26% of the circumference of the cylindrical balloon wall.


87. The catheter of any of examples 51-86 wherein the plurality of windows comprises a hydrophilic polymer.


88. The catheter of any of examples 51-87 wherein the plurality of windows comprises a hydrophilic polymer selected from the group consisting of hydrophilic Pebax, hydrophilic nylons, hydrophilic polyesters, or block co-polymers with built-in hydrophilic blocks, Pebax MV1074, Pebax MV 1041, Pebax MP 1878, Pebax MV-3000, Pebax MH-1657.


89. The catheter of any of examples 87-88 wherein the plurality of windows comprises the hydrophilic polymer blended with a second polymer.


90. The catheter of example 89 wherein the second polymer is selected from a group consisting of Pebax 6333, Pebax 7033, Pebax 7233, Nylon 12, Vestamid L2101F, Grilamid L20, and Grilamid L25.


91. The catheter of any of examples 87-90 wherein the hydrophilic polymer has between 20% to 50% hydrophilicity.


92. The catheter of any of examples 51-91 wherein the balloon wall comprises a non-hydrophilic polymer.


93. The catheter of any of examples 51-92 wherein the balloon comprises a first layer and a second layer.


94. The intravascular catheter of example 70 wherein the first layer is electrically conductive and the second layer is non-electrically conductive.


95. The intravascular catheter of any of examples 93-94 wherein the first layer is inside the second layer.


96. The intravascular catheter of any of examples 93-95 wherein plurality of windows do not include the second layer.


97. The intravascular catheter of any of examples 93-96 wherein the plurality of windows consist essentially of the first layer.


98. The intravascular catheter of any of examples 51-97 wherein the electrode extends for at least 50% the length of the balloon.


99. The intravascular catheter of any of examples 51-97 wherein the electrode extends for at least 80% the length of the balloon.


100. The intravascular catheter of any of examples 51-99 wherein the electrode extends for the length of the balloon.


101. The intravascular catheter of any of examples 51-99 wherein the electrode is helically shaped.


102. The intravascular catheter of any of examples 51-101 wherein the elongate member extends the length of the balloon.


103. The intravascular catheter of example 102 wherein the electrode is disposed on an outer surface of the elongate member.


104. The intravascular catheter of any of examples 102-103 wherein the elongate member comprises a guidewire lumen having an open distal end.


105. The intravascular catheter of any of examples 102-104 wherein the elongate member further comprises a fluid supply lumen having an opening fluidly connected to the balloon lumen.


106. The intravascular catheter of example 105 wherein the elongate member further comprises a fluid return lumen having an opening fluidly connected to the shaft.


107. The intravascular catheter of example 106 wherein the fluid supply lumen opening is distal the fluid return lumen opening.


108. The intravascular catheter of example 107 wherein the fluid supply lumen opening is in a distal waist of the balloon.


109. The intravascular catheter of example 108 wherein the fluid return lumen opening is in a proximal waist of the balloon.


110. The intravascular catheter of any of examples 51-109 further comprising a temperature sensor.


111. The intravascular catheter of example 110 wherein the temperature sensor is disposed on the elongate member.


112. The intravascular catheter of example 110 wherein the temperature sensor is disposed on the balloon.


113. A method of nerve modulation, comprising:


providing a catheter according to any of examples 1-112;


moving the balloon to a region of interest;


inflating the balloon with an electrically conductive fluid; and


activating the electrode.


114. The method of example 113 wherein the step of moving the balloon to a region of interest includes the step of advancing the catheter within a blood vessel.


115. The method of any of examples 113-114 wherein the step of moving the balloon to a region of interest includes the step of advancing the catheter along a guidewire.


116. The method of any of examples 113-115 wherein the step of inflating the balloon includes the step of contacting the outer wall of the balloon to the region of interest.


117. The method of example 116 further comprising the step of circulating the fluid through the balloon at a rate of between 5 ml/min and 10 ml/min.


118. The method of any of examples 114-117 wherein the electrically conductive fluid comprises saline.


119. The method of any of examples 114-118 wherein the electrically conductive fluid comprises a hypertonic solution.


120. The method of any of examples 114-119 wherein the electrically conductive fluid comprises a contrast solution.


121. The method of any of examples 113-120 further comprising the step of hydrating the balloon prior to moving the balloon to a region of interest.


122. The method of example 121 wherein the step of hydrating the balloon comprises the step of soaking the balloon in a saline solution.


123. The method of example 72 wherein the step of soaking the balloon in a saline solution involves soaking of soaking the balloon in a saline solution for at least one minute.


124. The method of example 72 wherein the step of soaking the balloon in a saline solution involves soaking of soaking the balloon in a saline solution for at least five minutes.


Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and principles of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth hereinabove. All publications and patents are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.

Claims
  • 1. An intravascular catheter, comprising: an elongate member having a proximal end and a distal end;a balloon having an interior surface, and exterior surface, a lumen defined by the interior surface and comprising three or more sections that are permeable to RF radiation extending from the interior surface of the balloon to the exterior surface of the balloon and at least one non-electrically conductive section; andan electrode disposed in the balloon:wherein the balloon comprises a first layer and a second laver; andwherein the first layer is permeable to RF radiation and the second layer is non-electrically conductive.
  • 2. The intravascular catheter of claim 1, wherein the three or more sections that are permeable to RF radiation are spaced circumferentially and longitudinally with respect to each other.
  • 3. The intravascular catheter of claim 1, further comprising a temperature sensor.
  • 4. The intravascular catheter of any of claim 1, wherein the three or more sections that are permeable to RF radiation each comprise a hydrophilic polymer.
  • 5. The intravascular catheter of claim 4, wherein the hydrophilic polymer is hydrophilic polyurethane.
  • 6. The catheter of claim 1, wherein the three or more sections that are permeable to RF radiation each comprise the hydrophilic polymer blended with a second polymer.
  • 7. The catheter of claim 6, wherein the second polymer is selected from a group consisting of Pebax 6333, Pebax 7033, Pebax 7233, Nylon 12, Vestamid L2101F, Grilamid L20, and Grilamid L25.
  • 8. The catheter of claim 7, wherein the hydrophilic polymer has between 20% to 50% hydrophilicity.
  • 9. The catheter of claim 1, wherein the non-electrically conductive section comprises a non-hydrophilic polymer.
  • 10. The intravascular catheter of claim 1, wherein the first layer is inside the second layer.
  • 11. The intravascular catheter of claim 1, wherein the three or more sections that are permeable to RF radiation do not include the second layer.
  • 12. The intravascular catheter of claim 1, wherein the three or more sections that are permeable to RF radiation consist essentially of the first layer.
  • 13. The intravascular catheter of claim 1, wherein the electrode extends under three or more sections that are permeable to RF.
  • 14. The intravascular catheter of claim 1, wherein the electrode is helically shaped.
  • 15. The intravascular catheter of claim 14, wherein the elongate member extends the length of the balloon.
  • 16. The intravascular catheter of claim 1, wherein the elongate member comprises a guidewire lumen having an open distal end.
  • 17. The intravascular catheter of claim 1, wherein the elongate member further comprises a fluid supply lumen having an opening fluidly connected to the balloon lumen and a fluid return lumen having an opening fluidly connected to the shaft.
  • 18. The intravascular catheter of claim 17, wherein the fluid supply lumen opening is distal the three or more sections that are permeable to RF radiation.
  • 19. The intravascular catheter of claim 17, further comprising a fluid supply, wherein the first layer is more compliant than the second layer, wherein the three or more sections that are permeable to RF radiation are in the form of RF permeable windows, and wherein pressure provided by fluid from the fluid supply causes the RF permeable windows to bulge out.
  • 20. The intravascular catheter of claim 1, wherein the three or more sections that are permeable to RF radiation are in the form of RF permeable windows, and wherein the RF permeable windows are arranged so that any line drawn longitudinally along the balloon wall passes through at least one RF permeable window.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. §119 to U.S. Provisional Application Ser. No. 61/580,972, filed Dec. 28, 2011; to U.S. Provisional Application Ser. No. 61/605,615, filed Oct. Mar. 1, 2012; and to U.S. Provisional Application Ser. No. 61/605,624, filed Oct. Mar. 1, 2012, all of which are herein incorporated by reference.

US Referenced Citations (1473)
Number Name Date Kind
164184 Kiddee Jun 1875 A
1167014 O'Brien Jan 1916 A
2505358 Gusberg et al. Apr 1950 A
2701559 Cooper Feb 1955 A
3108593 Glassman Oct 1963 A
3108594 Glassman Oct 1963 A
3540431 Mobin Nov 1970 A
3952747 Kimmell Apr 1976 A
3996938 Clark, III Dec 1976 A
4046150 Schwartz et al. Sep 1977 A
4290427 Chin Sep 1981 A
4402686 Medel Sep 1983 A
4483341 Witteles et al. Nov 1984 A
4574804 Kurwa Mar 1986 A
4587975 Salo et al. May 1986 A
4649936 Ungar et al. Mar 1987 A
4682596 Bales et al. Jul 1987 A
4709698 Johnston et al. Dec 1987 A
4765331 Petruzzi et al. Aug 1988 A
4770653 Shturman Sep 1988 A
4784132 Fox et al. Nov 1988 A
4784162 Ricks et al. Nov 1988 A
4785806 Deckelbaum et al. Nov 1988 A
4788975 Shturman et al. Dec 1988 A
4790310 Ginsburg et al. Dec 1988 A
4799479 Spears Jan 1989 A
4823791 D'Amelio et al. Apr 1989 A
4830003 Wolff et al. May 1989 A
4849484 Heard Jul 1989 A
4862886 Clarke et al. Sep 1989 A
4887605 Angelsen et al. Dec 1989 A
4920979 Bullara et al. May 1990 A
4938766 Jarvik Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4976711 Parins et al. Dec 1990 A
5034010 Kittrell et al. Jul 1991 A
5052402 Bencini et al. Oct 1991 A
5053033 Clarke et al. Oct 1991 A
5071424 Reger et al. Dec 1991 A
5074871 Groshong et al. Dec 1991 A
5098429 Sterzer et al. Mar 1992 A
5098431 Rydell Mar 1992 A
5109859 Jenkins May 1992 A
5125928 Parins et al. Jun 1992 A
5129396 Rosen et al. Jul 1992 A
5139496 Hed Aug 1992 A
5143836 Hartman et al. Sep 1992 A
5156610 Reger et al. Oct 1992 A
5158564 Schnepp-Pesch Oct 1992 A
5170802 Mehra Dec 1992 A
5178620 Eggers et al. Jan 1993 A
5178625 Groshong et al. Jan 1993 A
5190540 Lee Mar 1993 A
5211651 Reger et al. May 1993 A
5234407 Teirstein et al. Aug 1993 A
5242441 Avitall Sep 1993 A
5251634 Weinberg et al. Oct 1993 A
5255679 Imran Oct 1993 A
5263493 Avitall Nov 1993 A
5267954 Nita et al. Dec 1993 A
5277201 Stern et al. Jan 1994 A
5282484 Reger et al. Feb 1994 A
5286254 Shapland et al. Feb 1994 A
5295484 Marcus Mar 1994 A
5297564 Love et al. Mar 1994 A
5300068 Rosar et al. Apr 1994 A
5301683 Durkan Apr 1994 A
5304115 Pflueger et al. Apr 1994 A
5304121 Sahatjian Apr 1994 A
5304171 Gregory et al. Apr 1994 A
5304173 Kittrell et al. Apr 1994 A
5306250 March et al. Apr 1994 A
5312328 Nita et al. May 1994 A
5314466 Stern et al. May 1994 A
5322064 Lundquist Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5326341 Lew et al. Jul 1994 A
5326342 Pflueger et al. Jul 1994 A
5330518 Neilson et al. Jul 1994 A
5333614 Feiring Aug 1994 A
5342292 Nita et al. Aug 1994 A
5344395 Whalen et al. Sep 1994 A
5364392 Warner et al. Nov 1994 A
5365172 Hrovat et al. Nov 1994 A
5368557 Nita et al. Nov 1994 A
5368558 Nita et al. Nov 1994 A
5380274 Nita et al. Jan 1995 A
5380319 Saito et al. Jan 1995 A
5382228 Nita et al. Jan 1995 A
5383874 Jackson et al. Jan 1995 A
5383917 Desai et al. Jan 1995 A
5397301 Pflueger et al. Mar 1995 A
5397339 Desai Mar 1995 A
5401272 Perkins et al. Mar 1995 A
5403311 Abele et al. Apr 1995 A
5405318 Nita et al. Apr 1995 A
5405346 Grundy et al. Apr 1995 A
5409000 Imran Apr 1995 A
5417672 Nita et al. May 1995 A
5419767 Eggers et al. May 1995 A
5427118 Nita et al. Jun 1995 A
5432876 Appeldorn et al. Jul 1995 A
5441498 Perkins et al. Aug 1995 A
5447509 Mills et al. Sep 1995 A
5451207 Yock et al. Sep 1995 A
5453091 Taylor et al. Sep 1995 A
5454788 Walker et al. Oct 1995 A
5454809 Janssen Oct 1995 A
5455029 Hartman et al. Oct 1995 A
5456682 Edwards et al. Oct 1995 A
5457042 Hartman et al. Oct 1995 A
5471982 Edwards et al. Dec 1995 A
5474530 Passafaro et al. Dec 1995 A
5478351 Meade et al. Dec 1995 A
5496311 Abele et al. Mar 1996 A
5496312 Klicek et al. Mar 1996 A
5498261 Strul Mar 1996 A
5505201 Grill et al. Apr 1996 A
5505730 Edwards Apr 1996 A
5507744 Tay et al. Apr 1996 A
5522873 Jackman et al. Jun 1996 A
5531520 Grimson et al. Jul 1996 A
5540656 Pflueger et al. Jul 1996 A
5540679 Fram et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5542917 Nita et al. Aug 1996 A
5545161 Imran Aug 1996 A
5562100 Kittrell et al. Oct 1996 A
5571122 Kelly et al. Nov 1996 A
5571151 Gregory Nov 1996 A
5573531 Gregory et al. Nov 1996 A
5573533 Strul Nov 1996 A
5584831 McKay Dec 1996 A
5584872 Lafontaine et al. Dec 1996 A
5588962 Nicholas et al. Dec 1996 A
5599346 Edwards et al. Feb 1997 A
5601526 Chapelon et al. Feb 1997 A
5609606 O'Boyle et al. Mar 1997 A
5626576 Janssen May 1997 A
5630837 Crowley May 1997 A
5637090 McGee et al. Jun 1997 A
5643255 Organ Jul 1997 A
5643297 Nordgren et al. Jul 1997 A
5647847 Lafontaine et al. Jul 1997 A
5649923 Gregory et al. Jul 1997 A
5651780 Jackson et al. Jul 1997 A
5653684 Laptewicz et al. Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5665062 Houser Sep 1997 A
5665098 Kelly et al. Sep 1997 A
5666964 Meilus Sep 1997 A
5667490 Keith et al. Sep 1997 A
5672174 Gough et al. Sep 1997 A
5676693 Lafontaine Oct 1997 A
5678296 Fleischhacker et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
RE35656 Feinberg Nov 1997 E
5688266 Edwards et al. Nov 1997 A
5693015 Walker et al. Dec 1997 A
5693029 Leonhardt et al. Dec 1997 A
5693043 Kittrell et al. Dec 1997 A
5693082 Warner et al. Dec 1997 A
5695504 Gifford et al. Dec 1997 A
5697369 Long, Jr. et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5702386 Stern et al. Dec 1997 A
5702433 Taylor et al. Dec 1997 A
5706809 Littmann et al. Jan 1998 A
5713942 Stern et al. Feb 1998 A
5715819 Svenson et al. Feb 1998 A
5735846 Panescu et al. Apr 1998 A
5741214 Ouchi et al. Apr 1998 A
5741248 Stern et al. Apr 1998 A
5741249 Moss et al. Apr 1998 A
5743903 Stern et al. Apr 1998 A
5748347 Erickson May 1998 A
5749914 Janssen May 1998 A
5755682 Knudson et al. May 1998 A
5755715 Stern et al. May 1998 A
5755753 Knowlton et al. May 1998 A
5769847 Panescu et al. Jun 1998 A
5769880 Truckai et al. Jun 1998 A
5775338 Hastings Jul 1998 A
5776174 Van Tassel Jul 1998 A
5779698 Clayman et al. Jul 1998 A
5782760 Schaer Jul 1998 A
5785702 Murphy et al. Jul 1998 A
5797849 Vesely et al. Aug 1998 A
5797903 Swanson et al. Aug 1998 A
5800484 Gough et al. Sep 1998 A
5800494 Campbell et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5810803 Moss et al. Sep 1998 A
5810810 Tay et al. Sep 1998 A
5817092 Behl Oct 1998 A
5817113 Gifford et al. Oct 1998 A
5817144 Gregory et al. Oct 1998 A
5823956 Roth et al. Oct 1998 A
5827203 Nita et al. Oct 1998 A
5827268 Laufer Oct 1998 A
5829447 Stevens et al. Nov 1998 A
5830213 Panescu et al. Nov 1998 A
5830222 Makower Nov 1998 A
5832228 Holden et al. Nov 1998 A
5833593 Liprie Nov 1998 A
5836874 Swanson et al. Nov 1998 A
5840076 Swanson et al. Nov 1998 A
5843016 Lugnani et al. Dec 1998 A
5846238 Jackson et al. Dec 1998 A
5846239 Swanson et al. Dec 1998 A
5846245 McCarthy et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5853411 Whayne et al. Dec 1998 A
5855614 Stevens et al. Jan 1999 A
5860974 Abele Jan 1999 A
5865801 Houser Feb 1999 A
5868735 Lafontaine et al. Feb 1999 A
5868736 Swanson et al. Feb 1999 A
5871483 Jackson et al. Feb 1999 A
5871524 Knowlton et al. Feb 1999 A
5875782 Ferrari et al. Mar 1999 A
5876369 Houser Mar 1999 A
5876374 Alba et al. Mar 1999 A
5876397 Edelman et al. Mar 1999 A
5879348 Owens et al. Mar 1999 A
5891114 Chien et al. Apr 1999 A
5891135 Jackson et al. Apr 1999 A
5891136 McGee et al. Apr 1999 A
5891138 Tu et al. Apr 1999 A
5895378 Nita Apr 1999 A
5897552 Edwards et al. Apr 1999 A
5902328 Lafontaine et al. May 1999 A
5904651 Swanson et al. May 1999 A
5904667 Falwell et al. May 1999 A
5904697 Gifford et al. May 1999 A
5904709 Arndt et al. May 1999 A
5906614 Stern et al. May 1999 A
5906623 Peterson May 1999 A
5906636 Casscells et al. May 1999 A
5916192 Nita et al. Jun 1999 A
5916227 Keith et al. Jun 1999 A
5916239 Geddes et al. Jun 1999 A
5919219 Knowlton et al. Jul 1999 A
5924424 Stevens et al. Jul 1999 A
5925038 Panescu et al. Jul 1999 A
5934284 Plaia et al. Aug 1999 A
5935063 Nguyen Aug 1999 A
5938670 Keith et al. Aug 1999 A
5947977 Slepian et al. Sep 1999 A
5948011 Knowlton et al. Sep 1999 A
5951494 Wang et al. Sep 1999 A
5951539 Nita et al. Sep 1999 A
5954717 Behl et al. Sep 1999 A
5957882 Nita et al. Sep 1999 A
5957941 Ream et al. Sep 1999 A
5957969 Warner et al. Sep 1999 A
5961513 Swanson et al. Oct 1999 A
5964757 Ponzi et al. Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5967978 Littmann et al. Oct 1999 A
5967984 Chu et al. Oct 1999 A
5971975 Mills et al. Oct 1999 A
5972026 Laufer et al. Oct 1999 A
5980563 Tu et al. Nov 1999 A
5989208 Nita et al. Nov 1999 A
5989284 Laufer Nov 1999 A
5993462 Pomeranz et al. Nov 1999 A
5997497 Nita et al. Dec 1999 A
5999678 Murphy et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6004316 Laufer et al. Dec 1999 A
6007514 Nita Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6012457 Lesh Jan 2000 A
6013033 Berger et al. Jan 2000 A
6014590 Whayne et al. Jan 2000 A
6022309 Celliers et al. Feb 2000 A
6024740 Lesh Feb 2000 A
6030611 Gorecki et al. Feb 2000 A
6032675 Rubinsky et al. Mar 2000 A
6033397 Laufer et al. Mar 2000 A
6033398 Farley et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6036689 Tu et al. Mar 2000 A
6041260 Stern et al. Mar 2000 A
6050994 Sherman et al. Apr 2000 A
6056744 Edwards May 2000 A
6056746 Goble et al. May 2000 A
6063085 Tay et al. May 2000 A
6066096 Smith et al. May 2000 A
6066139 Ryan et al. May 2000 A
6068638 Makower May 2000 A
6068653 Lafontaine May 2000 A
6071277 Farley et al. Jun 2000 A
6071278 Panescu et al. Jun 2000 A
6078839 Carson Jun 2000 A
6079414 Roth Jun 2000 A
6080171 Keith et al. Jun 2000 A
6081749 Ingle et al. Jun 2000 A
6086581 Reynolds et al. Jul 2000 A
6093166 Knudson et al. Jul 2000 A
6096021 Helm et al. Aug 2000 A
6099526 Whayne et al. Aug 2000 A
6102908 Tu et al. Aug 2000 A
6106477 Miesel et al. Aug 2000 A
6110187 Donlon et al. Aug 2000 A
6114311 Parmacek et al. Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6117128 Gregory Sep 2000 A
6120476 Fung et al. Sep 2000 A
6120516 Selmon et al. Sep 2000 A
6121775 Pearlman Sep 2000 A
6123679 Lafaut et al. Sep 2000 A
6123682 Knudson et al. Sep 2000 A
6123702 Swanson et al. Sep 2000 A
6123703 Tu et al. Sep 2000 A
6123718 Tu et al. Sep 2000 A
6129725 Tu et al. Oct 2000 A
6135997 Laufer et al. Oct 2000 A
6142991 Schatzberger et al. Nov 2000 A
6142993 Whayne et al. Nov 2000 A
6149647 Tu et al. Nov 2000 A
6152899 Farley et al. Nov 2000 A
6152912 Jansen et al. Nov 2000 A
6156046 Passafaro et al. Dec 2000 A
6158250 Tibbals et al. Dec 2000 A
6159187 Park et al. Dec 2000 A
6159225 Makower Dec 2000 A
6161048 Sluijter et al. Dec 2000 A
6162184 Swanson et al. Dec 2000 A
6165163 Chien et al. Dec 2000 A
6165172 Farley et al. Dec 2000 A
6165187 Reger et al. Dec 2000 A
6168594 Lafontaine et al. Jan 2001 B1
6171321 Gifford, III et al. Jan 2001 B1
6179832 Jones et al. Jan 2001 B1
6179835 Panescu et al. Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6183468 Swanson et al. Feb 2001 B1
6183486 Snow et al. Feb 2001 B1
6190379 Heuser et al. Feb 2001 B1
6191862 Swanson et al. Feb 2001 B1
6197021 Panescu et al. Mar 2001 B1
6200266 Shokrollahi et al. Mar 2001 B1
6203537 Adrian Mar 2001 B1
6203561 Ramee et al. Mar 2001 B1
6210406 Webster Apr 2001 B1
6211247 Goodman Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6219577 Brown, III et al. Apr 2001 B1
6228076 Winston et al. May 2001 B1
6228109 Tu et al. May 2001 B1
6231516 Keilman et al. May 2001 B1
6231587 Makower May 2001 B1
6235044 Root et al. May 2001 B1
6236883 Ciaccio et al. May 2001 B1
6237605 Vaska et al. May 2001 B1
6238389 Paddock et al. May 2001 B1
6238392 Long May 2001 B1
6241666 Pomeranz et al. Jun 2001 B1
6241753 Knowlton Jun 2001 B1
6245020 Moore et al. Jun 2001 B1
6245045 Stratienko Jun 2001 B1
6248126 Lesser et al. Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6258087 Edwards et al. Jul 2001 B1
6273886 Edwards et al. Aug 2001 B1
6280466 Kugler et al. Aug 2001 B1
6283935 Laufer et al. Sep 2001 B1
6283959 Lalonde et al. Sep 2001 B1
6284743 Parmacek et al. Sep 2001 B1
6287323 Hammerslag Sep 2001 B1
6290696 Lafontaine Sep 2001 B1
6292695 Webster, Jr. et al. Sep 2001 B1
6293942 Goble et al. Sep 2001 B1
6293943 Panescu et al. Sep 2001 B1
6296619 Brisken et al. Oct 2001 B1
6298256 Meyer Oct 2001 B1
6299379 Lewis Oct 2001 B1
6299623 Wulfman Oct 2001 B1
6309379 Willard et al. Oct 2001 B1
6309399 Barbut et al. Oct 2001 B1
6311090 Knowlton Oct 2001 B1
6317615 KenKnight et al. Nov 2001 B1
6319242 Patterson et al. Nov 2001 B1
6319251 Tu et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6325799 Goble Dec 2001 B1
6328699 Eigler et al. Dec 2001 B1
6346074 Roth Feb 2002 B1
6346104 Daly et al. Feb 2002 B2
6350248 Knudson et al. Feb 2002 B1
6350276 Knowlton Feb 2002 B1
6353751 Swanson et al. Mar 2002 B1
6355029 Joye et al. Mar 2002 B1
6357447 Swanson et al. Mar 2002 B1
6361519 Knudson et al. Mar 2002 B1
6364840 Crowley Apr 2002 B1
6371965 Gifford, III et al. Apr 2002 B2
6375668 Gifford et al. Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6379352 Reynolds et al. Apr 2002 B1
6379373 Sawhney et al. Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6383151 Diederich et al. May 2002 B1
6387105 Gifford, III et al. May 2002 B1
6387380 Knowlton May 2002 B1
6389311 Whayne et al. May 2002 B1
6389314 Feiring May 2002 B2
6391024 Sun et al. May 2002 B1
6394096 Constantz May 2002 B1
6394956 Chandrasekaran et al. May 2002 B1
6398780 Farley et al. Jun 2002 B1
6398782 Pecor et al. Jun 2002 B1
6398792 O'Connor Jun 2002 B1
6401720 Stevens et al. Jun 2002 B1
6402719 Ponzi et al. Jun 2002 B1
6405090 Knowlton Jun 2002 B1
6409723 Edwards Jun 2002 B1
6413255 Stern Jul 2002 B1
6421559 Pearlman Jul 2002 B1
6423057 He et al. Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6427118 Suzuki Jul 2002 B1
6428534 Joye et al. Aug 2002 B1
6428536 Panescu et al. Aug 2002 B2
6430446 Knowlton Aug 2002 B1
6432102 Joye et al. Aug 2002 B2
6436056 Wang et al. Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6440125 Rentrop Aug 2002 B1
6442413 Silver Aug 2002 B1
6443965 Gifford, III et al. Sep 2002 B1
6445939 Swanson et al. Sep 2002 B1
6447505 McGovern et al. Sep 2002 B2
6447509 Bonnet et al. Sep 2002 B1
6451034 Gifford, III et al. Sep 2002 B1
6451044 Naghavi et al. Sep 2002 B1
6453202 Knowlton Sep 2002 B1
6454737 Nita et al. Sep 2002 B1
6454757 Nita et al. Sep 2002 B1
6454775 Demarais et al. Sep 2002 B1
6458098 Kanesaka Oct 2002 B1
6461378 Knowlton Oct 2002 B1
6468276 McKay Oct 2002 B1
6468297 Williams et al. Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6470219 Edwards et al. Oct 2002 B1
6471696 Berube et al. Oct 2002 B1
6475213 Whayne et al. Nov 2002 B1
6475215 Tanrisever Nov 2002 B1
6475238 Fedida et al. Nov 2002 B1
6477426 Fenn et al. Nov 2002 B1
6480745 Nelson et al. Nov 2002 B2
6481704 Koster et al. Nov 2002 B1
6482202 Goble et al. Nov 2002 B1
6484052 Visuri et al. Nov 2002 B1
6485489 Teirstein et al. Nov 2002 B2
6488679 Swanson et al. Dec 2002 B1
6489307 Phillips et al. Dec 2002 B1
6491705 Gifford, III et al. Dec 2002 B2
6494891 Cornish et al. Dec 2002 B1
6497711 Plaia et al. Dec 2002 B1
6500172 Panescu et al. Dec 2002 B1
6500174 Maguire et al. Dec 2002 B1
6508765 Suorsa et al. Jan 2003 B2
6508804 Sarge et al. Jan 2003 B2
6508815 Strul et al. Jan 2003 B1
6511478 Burnside et al. Jan 2003 B1
6511496 Huter et al. Jan 2003 B1
6511500 Rahme Jan 2003 B1
6514236 Stratienko Feb 2003 B1
6514245 Williams et al. Feb 2003 B1
6514248 Eggers et al. Feb 2003 B1
6517534 McGovern et al. Feb 2003 B1
6517572 Kugler et al. Feb 2003 B2
6522913 Swanson et al. Feb 2003 B2
6522926 Kieval et al. Feb 2003 B1
6524299 Tran et al. Feb 2003 B1
6527765 Kelman et al. Mar 2003 B2
6527769 Langberg et al. Mar 2003 B2
6540761 Houser Apr 2003 B2
6542781 Koblish et al. Apr 2003 B1
6544780 Wang Apr 2003 B1
6546272 MacKinnon et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6549800 Atalar et al. Apr 2003 B1
6552796 Magnin et al. Apr 2003 B2
6554780 Sampson et al. Apr 2003 B1
6558381 Ingle et al. May 2003 B2
6558382 Jahns et al. May 2003 B2
6564096 Mest May 2003 B2
6565582 Gifford, III et al. May 2003 B2
6569109 Sakurai et al. May 2003 B2
6569177 Dillard et al. May 2003 B1
6570659 Schmitt May 2003 B2
6572551 Smith et al. Jun 2003 B1
6572612 Stewart et al. Jun 2003 B2
6577902 Laufer et al. Jun 2003 B1
6579308 Jansen et al. Jun 2003 B1
6579311 Makower Jun 2003 B1
6582423 Thapliyal et al. Jun 2003 B1
6589238 Edwards et al. Jul 2003 B2
6592526 Lenker Jul 2003 B1
6592567 Levin et al. Jul 2003 B1
6595959 Stratienko Jul 2003 B1
6600956 Maschino et al. Jul 2003 B2
6602242 Fung Aug 2003 B1
6602246 Joye et al. Aug 2003 B1
6605084 Acker et al. Aug 2003 B2
6623452 Chien et al. Sep 2003 B2
6623453 Guibert et al. Sep 2003 B1
6632193 Davison et al. Oct 2003 B1
6632196 Houser Oct 2003 B1
6645223 Boyle et al. Nov 2003 B2
6648854 Patterson et al. Nov 2003 B1
6648878 Lafontaine Nov 2003 B2
6648879 Joye et al. Nov 2003 B2
6651672 Roth Nov 2003 B2
6652513 Panescu et al. Nov 2003 B2
6652515 Maguire et al. Nov 2003 B1
6656136 Weng et al. Dec 2003 B1
6658279 Swanson et al. Dec 2003 B2
6659981 Stewart et al. Dec 2003 B2
6666858 Lafontaine Dec 2003 B2
6666863 Wentzel et al. Dec 2003 B2
6669655 Acker et al. Dec 2003 B1
6669692 Nelson et al. Dec 2003 B1
6673040 Samson et al. Jan 2004 B1
6673064 Rentrop Jan 2004 B1
6673066 Werneth Jan 2004 B2
6673090 Root et al. Jan 2004 B2
6673101 Fitzgerald et al. Jan 2004 B1
6673290 Whayne et al. Jan 2004 B1
6676678 Gifford, III et al. Jan 2004 B2
6679268 Stevens et al. Jan 2004 B2
6681773 Murphy et al. Jan 2004 B2
6682541 Gifford, III et al. Jan 2004 B1
6684098 Oshio et al. Jan 2004 B2
6685732 Kramer Feb 2004 B2
6685733 Dae et al. Feb 2004 B1
6689086 Nita et al. Feb 2004 B1
6689148 Sawhney et al. Feb 2004 B2
6690181 Dowdeswell et al. Feb 2004 B1
6692490 Edwards Feb 2004 B1
6695830 Vigil et al. Feb 2004 B2
6695857 Gifford, III et al. Feb 2004 B2
6699241 Rappaport et al. Mar 2004 B2
6699257 Gifford, III et al. Mar 2004 B2
6702748 Nita et al. Mar 2004 B1
6702811 Stewart et al. Mar 2004 B2
6706010 Miki et al. Mar 2004 B1
6706011 Murphy-Chutorian et al. Mar 2004 B1
6706037 Zvuloni et al. Mar 2004 B2
6709431 Lafontaine Mar 2004 B2
6711429 Gilboa et al. Mar 2004 B1
6712815 Sampson et al. Mar 2004 B2
6714822 King et al. Mar 2004 B2
6716184 Vaezy et al. Apr 2004 B2
6720350 Kunz et al. Apr 2004 B2
6723043 Kleeman et al. Apr 2004 B2
6723064 Babaev Apr 2004 B2
6736811 Panescu et al. May 2004 B2
6743184 Sampson et al. Jun 2004 B2
6746401 Panescu Jun 2004 B2
6746464 Makower Jun 2004 B1
6746474 Saadat Jun 2004 B2
6748953 Sherry et al. Jun 2004 B2
6749607 Edwards et al. Jun 2004 B2
6752805 Maguire et al. Jun 2004 B2
6760616 Hoey et al. Jul 2004 B2
6763261 Casscells, III et al. Jul 2004 B2
6764501 Ganz Jul 2004 B2
6769433 Zikorus et al. Aug 2004 B2
6770070 Balbierz Aug 2004 B1
6771996 Bowe et al. Aug 2004 B2
6773433 Stewart et al. Aug 2004 B2
6786900 Joye et al. Sep 2004 B2
6786901 Joye et al. Sep 2004 B2
6786904 Döscher et al. Sep 2004 B2
6788977 Fenn et al. Sep 2004 B2
6790206 Panescu Sep 2004 B2
6790222 Kugler et al. Sep 2004 B2
6796981 Wham et al. Sep 2004 B2
6797933 Mendis et al. Sep 2004 B1
6797960 Spartiotis et al. Sep 2004 B1
6800075 Mische et al. Oct 2004 B2
6802857 Walsh et al. Oct 2004 B1
6807444 Tu et al. Oct 2004 B2
6811550 Holland et al. Nov 2004 B2
6813520 Truckai et al. Nov 2004 B2
6814730 Li Nov 2004 B2
6814733 Schwartz et al. Nov 2004 B2
6823205 Jara Nov 2004 B1
6824516 Batten et al. Nov 2004 B2
6827726 Parodi Dec 2004 B2
6827926 Robinson et al. Dec 2004 B2
6829497 Mogul Dec 2004 B2
6830568 Kesten et al. Dec 2004 B1
6837886 Collins et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6845267 Harrison Jan 2005 B2
6847848 Sterzer Jan 2005 B2
6849073 Hoey et al. Feb 2005 B2
6849075 Bertolero et al. Feb 2005 B2
6853425 Kim et al. Feb 2005 B2
6855123 Nita Feb 2005 B2
6855143 Davison Feb 2005 B2
6869431 Maguire et al. Mar 2005 B2
6872183 Sampson et al. Mar 2005 B2
6884260 Kugler et al. Apr 2005 B2
6889694 Hooven May 2005 B2
6893436 Woodard et al. May 2005 B2
6895077 Karellas et al. May 2005 B2
6895265 Silver May 2005 B2
6898454 Atalar et al. May 2005 B2
6899711 Stewart et al. May 2005 B2
6899718 Gifford, III et al. May 2005 B2
6905494 Yon et al. Jun 2005 B2
6908462 Joye et al. Jun 2005 B2
6909009 Koridze Jun 2005 B2
6911026 Hall et al. Jun 2005 B1
6915806 Pacek et al. Jul 2005 B2
6923805 LaFontaine et al. Aug 2005 B1
6923808 Taimisto Aug 2005 B2
6926246 Ginggen Aug 2005 B2
6926713 Rioux et al. Aug 2005 B2
6926716 Baker et al. Aug 2005 B2
6929009 Makower et al. Aug 2005 B2
6929632 Nita et al. Aug 2005 B2
6929639 Lafontaine Aug 2005 B2
6932776 Carr Aug 2005 B2
6936047 Nasab et al. Aug 2005 B2
6942620 Nita et al. Sep 2005 B2
6942657 Sinofsky et al. Sep 2005 B2
6942677 Nita et al. Sep 2005 B2
6942692 Landau et al. Sep 2005 B2
6949097 Stewart et al. Sep 2005 B2
6949121 Laguna Sep 2005 B1
6952615 Satake Oct 2005 B2
6953425 Brister Oct 2005 B2
6955174 Joye et al. Oct 2005 B2
6955175 Stevens et al. Oct 2005 B2
6959711 Murphy et al. Nov 2005 B2
6960207 Vanney et al. Nov 2005 B2
6962584 Stone et al. Nov 2005 B1
6964660 Maguire et al. Nov 2005 B2
6966908 Maguire et al. Nov 2005 B2
6972015 Joye et al. Dec 2005 B2
6972024 Kilpatrick et al. Dec 2005 B1
6974456 Edwards et al. Dec 2005 B2
6978174 Gelfand et al. Dec 2005 B2
6979329 Burnside et al. Dec 2005 B2
6979420 Weber Dec 2005 B2
6984238 Gifford, III et al. Jan 2006 B2
6985774 Kieval et al. Jan 2006 B2
6986739 Warren et al. Jan 2006 B2
6989009 Lafontaine Jan 2006 B2
6989010 Francischelli et al. Jan 2006 B2
6991617 Hektner et al. Jan 2006 B2
7001378 Yon et al. Feb 2006 B2
7006858 Silver et al. Feb 2006 B2
7022105 Edwards Apr 2006 B1
7022120 Lafontaine Apr 2006 B2
7025767 Schaefer et al. Apr 2006 B2
7033322 Silver Apr 2006 B2
7033372 Cahalan Apr 2006 B1
7041098 Farley et al. May 2006 B2
7050848 Hoey et al. May 2006 B2
7063670 Sampson et al. Jun 2006 B2
7063679 Maguire et al. Jun 2006 B2
7063719 Jansen et al. Jun 2006 B2
7066895 Podany Jun 2006 B2
7066900 Botto et al. Jun 2006 B2
7066904 Rosenthal et al. Jun 2006 B2
7072720 Puskas Jul 2006 B2
7074217 Strul et al. Jul 2006 B2
7081112 Joye et al. Jul 2006 B2
7081114 Rashidi Jul 2006 B2
7083614 Fjield et al. Aug 2006 B2
7084276 Vu et al. Aug 2006 B2
7087026 Callister et al. Aug 2006 B2
7087051 Bourne et al. Aug 2006 B2
7087052 Sampson et al. Aug 2006 B2
7087053 Vanney Aug 2006 B2
7089065 Westlund et al. Aug 2006 B2
7097641 Arless et al. Aug 2006 B1
7100614 Stevens et al. Sep 2006 B2
7101368 Lafontaine Sep 2006 B2
7104983 Grasso, III et al. Sep 2006 B2
7104987 Biggs et al. Sep 2006 B2
7108715 Lawrence-Brown et al. Sep 2006 B2
7112196 Brosch et al. Sep 2006 B2
7112198 Satake Sep 2006 B2
7112211 Gifford, III et al. Sep 2006 B2
7122019 Kesten et al. Oct 2006 B1
7122033 Wood Oct 2006 B2
7134438 Makower et al. Nov 2006 B2
7137963 Nita et al. Nov 2006 B2
7137980 Buysse et al. Nov 2006 B2
7153315 Miller Dec 2006 B2
7155271 Halperin et al. Dec 2006 B2
7157491 Mewshaw et al. Jan 2007 B2
7157492 Mewshaw et al. Jan 2007 B2
7158832 Kieval et al. Jan 2007 B2
7160296 Pearson et al. Jan 2007 B2
7162303 Levin et al. Jan 2007 B2
7165551 Edwards et al. Jan 2007 B2
7169144 Hoey et al. Jan 2007 B2
7172589 Lafontaine Feb 2007 B2
7172610 Heitzmann et al. Feb 2007 B2
7181261 Silver et al. Feb 2007 B2
7184811 Phan et al. Feb 2007 B2
7184827 Edwards Feb 2007 B1
7189227 Lafontaine Mar 2007 B2
7192427 Chapelon et al. Mar 2007 B2
7192586 Bander Mar 2007 B2
7197354 Sobe Mar 2007 B2
7198632 Lim et al. Apr 2007 B2
7200445 Dalbec et al. Apr 2007 B1
7201749 Govari et al. Apr 2007 B2
7203537 Mower Apr 2007 B2
7214234 Rapacki et al. May 2007 B2
7220233 Nita et al. May 2007 B2
7220239 Wilson et al. May 2007 B2
7220257 Lafontaine May 2007 B1
7220270 Sawhney et al. May 2007 B2
7232458 Saadat Jun 2007 B2
7232459 Greenberg et al. Jun 2007 B2
7238184 Megerman et al. Jul 2007 B2
7241273 Maguire et al. Jul 2007 B2
7241736 Hunter et al. Jul 2007 B2
7247141 Makin et al. Jul 2007 B2
7250041 Chiu et al. Jul 2007 B2
7250440 Mewshaw et al. Jul 2007 B2
7252664 Nasab et al. Aug 2007 B2
7252679 Fischell et al. Aug 2007 B2
7264619 Venturelli Sep 2007 B2
7279600 Mewshaw et al. Oct 2007 B2
7280863 Shachar Oct 2007 B2
7282213 Schroeder et al. Oct 2007 B2
7285119 Stewart et al. Oct 2007 B2
7285120 Im et al. Oct 2007 B2
7288089 Yon et al. Oct 2007 B2
7288096 Chin Oct 2007 B2
7291146 Steinke et al. Nov 2007 B2
7293562 Malecki et al. Nov 2007 B2
7294125 Phalen et al. Nov 2007 B2
7294126 Sampson et al. Nov 2007 B2
7294127 Leung et al. Nov 2007 B2
7297131 Nita Nov 2007 B2
7297475 Koiwai et al. Nov 2007 B2
7300433 Lane et al. Nov 2007 B2
7301108 Egitto et al. Nov 2007 B2
7310150 Guillermo et al. Dec 2007 B2
7313430 Urquhart et al. Dec 2007 B2
7314483 Landau et al. Jan 2008 B2
7317077 Averback et al. Jan 2008 B2
7323006 Andreas et al. Jan 2008 B2
7326206 Paul et al. Feb 2008 B2
7326226 Root et al. Feb 2008 B2
7326235 Edwards Feb 2008 B2
7326237 DePalma et al. Feb 2008 B2
7329236 Kesten et al. Feb 2008 B2
7335180 Nita et al. Feb 2008 B2
7335192 Keren et al. Feb 2008 B2
7338467 Lutter Mar 2008 B2
7341570 Keren et al. Mar 2008 B2
7343195 Strommer et al. Mar 2008 B2
7347857 Anderson et al. Mar 2008 B2
7348003 Salcedo et al. Mar 2008 B2
7352593 Zeng et al. Apr 2008 B2
7354927 Vu Apr 2008 B2
7359732 Kim et al. Apr 2008 B2
7361341 Salcedo et al. Apr 2008 B2
7364566 Elkins et al. Apr 2008 B2
7367970 Govari et al. May 2008 B2
7367975 Malecki et al. May 2008 B2
7371231 Rioux et al. May 2008 B2
7387126 Cox et al. Jun 2008 B2
7393338 Nita Jul 2008 B2
7396355 Goldman et al. Jul 2008 B2
7402151 Rosenman et al. Jul 2008 B2
7402312 Rosen et al. Jul 2008 B2
7404824 Webler et al. Jul 2008 B1
7406970 Zikorus et al. Aug 2008 B2
7407502 Strul et al. Aug 2008 B2
7407506 Makower Aug 2008 B2
7407671 McBride et al. Aug 2008 B2
7408021 Averback et al. Aug 2008 B2
7410486 Fuimaono et al. Aug 2008 B2
7413556 Zhang et al. Aug 2008 B2
7425212 Danek et al. Sep 2008 B1
7426409 Casscells, III et al. Sep 2008 B2
7435248 Taimisto et al. Oct 2008 B2
7447453 Kim et al. Nov 2008 B2
7449018 Kramer Nov 2008 B2
7452538 Ni et al. Nov 2008 B2
7473890 Grier et al. Jan 2009 B2
7476384 Ni et al. Jan 2009 B2
7479157 Weber et al. Jan 2009 B2
7481803 Kesten et al. Jan 2009 B2
7485104 Kieval Feb 2009 B2
7486805 Krattiger Feb 2009 B2
7487780 Hooven Feb 2009 B2
7493154 Bonner et al. Feb 2009 B2
7494485 Beck et al. Feb 2009 B2
7494486 Mische et al. Feb 2009 B2
7494488 Weber Feb 2009 B2
7494661 Sanders Feb 2009 B2
7495439 Wiggins Feb 2009 B2
7497858 Chapelon et al. Mar 2009 B2
7499745 Littrup et al. Mar 2009 B2
7500985 Saadat Mar 2009 B2
7505812 Eggers et al. Mar 2009 B1
7505816 Schmeling et al. Mar 2009 B2
7507233 Littrup et al. Mar 2009 B2
7507235 Keogh et al. Mar 2009 B2
7511494 Wedeen Mar 2009 B2
7512445 Truckai et al. Mar 2009 B2
7527643 Case et al. May 2009 B2
7529589 Williams et al. May 2009 B2
7540852 Nita et al. Jun 2009 B2
7540870 Babaev Jun 2009 B2
RE40863 Tay et al. Jul 2009 E
7556624 Laufer et al. Jul 2009 B2
7558625 Levin et al. Jul 2009 B2
7563247 Maguire et al. Jul 2009 B2
7566319 McAuley et al. Jul 2009 B2
7569052 Phan et al. Aug 2009 B2
7582111 Krolik et al. Sep 2009 B2
7584004 Caparso et al. Sep 2009 B2
7585835 Hill et al. Sep 2009 B2
7591996 Hwang et al. Sep 2009 B2
7597704 Frazier et al. Oct 2009 B2
7598228 Hattori et al. Oct 2009 B2
7599730 Hunter et al. Oct 2009 B2
7603166 Casscells, III et al. Oct 2009 B2
7604608 Nita et al. Oct 2009 B2
7604633 Truckai et al. Oct 2009 B2
7615015 Coleman Nov 2009 B2
7615072 Rust et al. Nov 2009 B2
7617005 Demarais et al. Nov 2009 B2
7620451 Demarais et al. Nov 2009 B2
7621902 Nita et al. Nov 2009 B2
7621929 Nita et al. Nov 2009 B2
7626015 Feinstein et al. Dec 2009 B2
7626235 Kinoshita Dec 2009 B2
7632268 Edwards et al. Dec 2009 B2
7632845 Vu et al. Dec 2009 B2
7635383 Gumm Dec 2009 B2
7640046 Pastore et al. Dec 2009 B2
7641633 Laufer et al. Jan 2010 B2
7641679 Joye et al. Jan 2010 B2
7646544 Batchko et al. Jan 2010 B2
7647115 Levin et al. Jan 2010 B2
7653438 Deem et al. Jan 2010 B2
7655006 Sauvageau et al. Feb 2010 B2
7662114 Seip et al. Feb 2010 B2
7664548 Amurthur et al. Feb 2010 B2
7670279 Gertner Mar 2010 B2
7670335 Keidar Mar 2010 B2
7671084 Mewshaw et al. Mar 2010 B2
7678104 Keidar Mar 2010 B2
7678106 Lee Mar 2010 B2
7678108 Chrisitian et al. Mar 2010 B2
7691080 Seward et al. Apr 2010 B2
7699809 Urmey Apr 2010 B2
7706882 Francischelli et al. Apr 2010 B2
7715912 Rezai et al. May 2010 B2
7717853 Nita May 2010 B2
7717909 Strul et al. May 2010 B2
7717948 Demarais et al. May 2010 B2
7722539 Carter et al. May 2010 B2
7725157 Dumoulin et al. May 2010 B2
7727178 Wilson et al. Jun 2010 B2
7736317 Stephens et al. Jun 2010 B2
7736360 Mody et al. Jun 2010 B2
7736362 Eberl et al. Jun 2010 B2
7738952 Yun et al. Jun 2010 B2
7740629 Anderson et al. Jun 2010 B2
7741299 Feinstein et al. Jun 2010 B2
7742795 Stone et al. Jun 2010 B2
7744594 Yamazaki et al. Jun 2010 B2
7753907 DiMatteo et al. Jul 2010 B2
7756583 Demarais et al. Jul 2010 B2
7758510 Nita et al. Jul 2010 B2
7758520 Griffin et al. Jul 2010 B2
7759315 Cuzzocrea et al. Jul 2010 B2
7766833 Lee et al. Aug 2010 B2
7766878 Tremaglio, Jr. et al. Aug 2010 B2
7766892 Keren et al. Aug 2010 B2
7767844 Lee et al. Aug 2010 B2
7769427 Shachar Aug 2010 B2
7771372 Wilson Aug 2010 B2
7771421 Stewart et al. Aug 2010 B2
7776967 Perry et al. Aug 2010 B2
7777486 Hargreaves et al. Aug 2010 B2
7780660 Bourne et al. Aug 2010 B2
7789876 Zikorus et al. Sep 2010 B2
7792568 Zhong et al. Sep 2010 B2
7799021 Leung et al. Sep 2010 B2
7803168 Gifford et al. Sep 2010 B2
7806871 Li et al. Oct 2010 B2
7811265 Hering et al. Oct 2010 B2
7811281 Rentrop Oct 2010 B1
7811313 Mon et al. Oct 2010 B2
7816511 Kawashima et al. Oct 2010 B2
7818053 Kassab Oct 2010 B2
7819866 Bednarek Oct 2010 B2
7822460 Halperin et al. Oct 2010 B2
7828837 Khoury Nov 2010 B2
7832407 Gertner Nov 2010 B2
7833220 Mon et al. Nov 2010 B2
7837676 Sinelnikov et al. Nov 2010 B2
7837720 Mon Nov 2010 B2
7841978 Gertner Nov 2010 B2
7846157 Kozel Dec 2010 B2
7846160 Payne et al. Dec 2010 B2
7846172 Makower Dec 2010 B2
7849860 Makower et al. Dec 2010 B2
7850685 Kunis et al. Dec 2010 B2
7853333 Demarais Dec 2010 B2
7854734 Biggs et al. Dec 2010 B2
7857756 Warren et al. Dec 2010 B2
7862565 Eder et al. Jan 2011 B2
7863897 Slocum, Jr. et al. Jan 2011 B2
7869854 Shachar et al. Jan 2011 B2
7873417 Demarais et al. Jan 2011 B2
7887538 Bleich et al. Feb 2011 B2
7894905 Pless et al. Feb 2011 B2
7896873 Hiller et al. Mar 2011 B2
7901400 Wham et al. Mar 2011 B2
7901402 Jones et al. Mar 2011 B2
7901420 Dunn Mar 2011 B2
7905862 Sampson Mar 2011 B2
7918850 Govari et al. Apr 2011 B2
7927370 Webler et al. Apr 2011 B2
7937143 Demarais et al. May 2011 B2
7938830 Saadat et al. May 2011 B2
7942874 Eder et al. May 2011 B2
7942928 Webler et al. May 2011 B2
7946976 Gertner May 2011 B2
7950397 Thapliyal et al. May 2011 B2
7955293 Nita et al. Jun 2011 B2
7956613 Wald Jun 2011 B2
7959627 Utley et al. Jun 2011 B2
7962854 Vance et al. Jun 2011 B2
7967782 Laufer et al. Jun 2011 B2
7967808 Fitzgerald et al. Jun 2011 B2
7972327 Eberl et al. Jul 2011 B2
7972330 Alejandro et al. Jul 2011 B2
7983751 Zdeblick et al. Jul 2011 B2
8001976 Gertner Aug 2011 B2
8007440 Magnin et al. Aug 2011 B2
8012147 Lafontaine Sep 2011 B2
8019435 Hastings et al. Sep 2011 B2
8021362 Deem et al. Sep 2011 B2
8021413 Dierking et al. Sep 2011 B2
8025661 Arnold et al. Sep 2011 B2
8027718 Spinner et al. Sep 2011 B2
8031927 Karl et al. Oct 2011 B2
8033284 Porter et al. Oct 2011 B2
8048144 Thistle et al. Nov 2011 B2
8052636 Moll et al. Nov 2011 B2
8052700 Dunn Nov 2011 B2
8062289 Babaev Nov 2011 B2
8075580 Makower Dec 2011 B2
8080006 Lafontaine et al. Dec 2011 B2
8088127 Mayse et al. Jan 2012 B2
8116883 Williams et al. Feb 2012 B2
8119183 O'Donoghue et al. Feb 2012 B2
8120518 Jang et al. Feb 2012 B2
8123741 Marrouche et al. Feb 2012 B2
8128617 Bencini et al. Mar 2012 B2
8131371 Demarals et al. Mar 2012 B2
8131372 Levin et al. Mar 2012 B2
8131382 Asada Mar 2012 B2
8137274 Weng et al. Mar 2012 B2
8140170 Rezai et al. Mar 2012 B2
8143316 Ueno Mar 2012 B2
8145316 Deem et al. Mar 2012 B2
8145317 Demarais et al. Mar 2012 B2
8150518 Levin et al. Apr 2012 B2
8150519 Demarais et al. Apr 2012 B2
8150520 Demarais et al. Apr 2012 B2
8152830 Gumm Apr 2012 B2
8162933 Francischelli et al. Apr 2012 B2
8175711 Demarais et al. May 2012 B2
8187261 Watson May 2012 B2
8190238 Moll et al. May 2012 B2
8192053 Owen et al. Jun 2012 B2
8198611 LaFontaine et al. Jun 2012 B2
8214056 Hoffer et al. Jul 2012 B2
8221407 Phan et al. Jul 2012 B2
8226637 Satake Jul 2012 B2
8231617 Satake Jul 2012 B2
8241217 Chiang et al. Aug 2012 B2
8257724 Cromack et al. Sep 2012 B2
8257725 Cromack et al. Sep 2012 B2
8260397 Ruff et al. Sep 2012 B2
8263104 Ho et al. Sep 2012 B2
8273023 Razavi Sep 2012 B2
8277379 Lau et al. Oct 2012 B2
8287524 Siegel Oct 2012 B2
8287532 Carroll et al. Oct 2012 B2
8292881 Brannan et al. Oct 2012 B2
8293703 Averback et al. Oct 2012 B2
8295902 Salahieh et al. Oct 2012 B2
8295912 Gertner Oct 2012 B2
8308722 Ormsby et al. Nov 2012 B2
8317776 Ferren et al. Nov 2012 B2
8317810 Stangenes et al. Nov 2012 B2
8329179 Ni et al. Dec 2012 B2
8336705 Okahisa Dec 2012 B2
8343031 Gertner Jan 2013 B2
8343145 Brannan Jan 2013 B2
8347891 Demarais et al. Jan 2013 B2
8353945 Andreas et al. Jan 2013 B2
8364237 Stone et al. Jan 2013 B2
8366615 Razavi Feb 2013 B2
8382697 Brenneman et al. Feb 2013 B2
8388680 Starksen et al. Mar 2013 B2
8396548 Perry et al. Mar 2013 B2
8398629 Thistle Mar 2013 B2
8401667 Gustus et al. Mar 2013 B2
8403881 Ferren et al. Mar 2013 B2
8406877 Smith et al. Mar 2013 B2
8409172 Moll et al. Apr 2013 B2
8409193 Young et al. Apr 2013 B2
8409195 Young Apr 2013 B2
8418362 Zerfas et al. Apr 2013 B2
8452988 Wang May 2013 B2
8454594 Demarais et al. Jun 2013 B2
8460358 Andreas et al. Jun 2013 B2
8465452 Kassab Jun 2013 B2
8469919 Ingle et al. Jun 2013 B2
8473067 Hastings et al. Jun 2013 B2
8480663 Ingle et al. Jul 2013 B2
8485992 Griffin et al. Jul 2013 B2
8486060 Kotmel et al. Jul 2013 B2
8486063 Werneth et al. Jul 2013 B2
8488591 Miali et al. Jul 2013 B2
20010007070 Stewart et al. Jul 2001 A1
20010039419 Francischelli et al. Nov 2001 A1
20020022864 Mahvi et al. Feb 2002 A1
20020042639 Murphy-Chutorian et al. Apr 2002 A1
20020045811 Kittrell et al. Apr 2002 A1
20020045890 Celliers et al. Apr 2002 A1
20020062146 Makower et al. May 2002 A1
20020065542 Lax et al. May 2002 A1
20020087151 Mody et al. Jul 2002 A1
20020095197 Lardo et al. Jul 2002 A1
20020107536 Hussein Aug 2002 A1
20020147480 Mamayek Oct 2002 A1
20020169444 Mest et al. Nov 2002 A1
20020198520 Coen et al. Dec 2002 A1
20030065317 Rudie et al. Apr 2003 A1
20030092995 Thompson May 2003 A1
20030139689 Shturman et al. Jul 2003 A1
20030195501 Sherman et al. Oct 2003 A1
20030199747 Michlitsch et al. Oct 2003 A1
20040010118 Zerhusen et al. Jan 2004 A1
20040019348 Stevens et al. Jan 2004 A1
20040024371 Plicchi et al. Feb 2004 A1
20040043030 Griffiths et al. Mar 2004 A1
20040064090 Keren et al. Apr 2004 A1
20040073206 Foley et al. Apr 2004 A1
20040088002 Boyle et al. May 2004 A1
20040093055 Bartorelli et al. May 2004 A1
20040106871 Hunyor et al. Jun 2004 A1
20040117032 Roth Jun 2004 A1
20040147915 Hasebe Jul 2004 A1
20040162555 Farley et al. Aug 2004 A1
20040167506 Chen Aug 2004 A1
20040186356 O'Malley et al. Sep 2004 A1
20040187875 He et al. Sep 2004 A1
20040193211 Voegele et al. Sep 2004 A1
20040220556 Cooper et al. Nov 2004 A1
20040243022 Carney et al. Dec 2004 A1
20040253304 Gross et al. Dec 2004 A1
20040267250 Yon et al. Dec 2004 A1
20050010095 Stewart et al. Jan 2005 A1
20050015125 Mioduski et al. Jan 2005 A1
20050080374 Esch et al. Apr 2005 A1
20050129616 Salcedo et al. Jun 2005 A1
20050137180 Robinson et al. Jun 2005 A1
20050143817 Hunter et al. Jun 2005 A1
20050148842 Wang et al. Jul 2005 A1
20050149069 Bertolero et al. Jul 2005 A1
20050149080 Hunter et al. Jul 2005 A1
20050149158 Hunter et al. Jul 2005 A1
20050149173 Hunter et al. Jul 2005 A1
20050149175 Hunter et al. Jul 2005 A1
20050154277 Tang et al. Jul 2005 A1
20050154445 Hunter et al. Jul 2005 A1
20050154453 Hunter et al. Jul 2005 A1
20050154454 Hunter et al. Jul 2005 A1
20050165389 Swain et al. Jul 2005 A1
20050165391 Maguire et al. Jul 2005 A1
20050165467 Hunter et al. Jul 2005 A1
20050165488 Hunter et al. Jul 2005 A1
20050175661 Hunter et al. Aug 2005 A1
20050175662 Hunter et al. Aug 2005 A1
20050175663 Hunter et al. Aug 2005 A1
20050177103 Hunter et al. Aug 2005 A1
20050177225 Hunter et al. Aug 2005 A1
20050181004 Hunter et al. Aug 2005 A1
20050181008 Hunter et al. Aug 2005 A1
20050181011 Hunter et al. Aug 2005 A1
20050181977 Hunter et al. Aug 2005 A1
20050182479 Bonsignore et al. Aug 2005 A1
20050183728 Hunter et al. Aug 2005 A1
20050186242 Hunter et al. Aug 2005 A1
20050186243 Hunter et al. Aug 2005 A1
20050191331 Hunter et al. Sep 2005 A1
20050203410 Jenkins Sep 2005 A1
20050209587 Joye et al. Sep 2005 A1
20050214205 Salcedo et al. Sep 2005 A1
20050214207 Salcedo et al. Sep 2005 A1
20050214208 Salcedo et al. Sep 2005 A1
20050214209 Salcedo et al. Sep 2005 A1
20050214210 Salcedo et al. Sep 2005 A1
20050214268 Cavanagh et al. Sep 2005 A1
20050228286 Messerly et al. Oct 2005 A1
20050228415 Gertner Oct 2005 A1
20050228460 Levin et al. Oct 2005 A1
20050232921 Rosen et al. Oct 2005 A1
20050234312 Suzuki et al. Oct 2005 A1
20050245862 Seward Nov 2005 A1
20050251116 Steinke et al. Nov 2005 A1
20050252553 Ginggen Nov 2005 A1
20050256398 Hastings et al. Nov 2005 A1
20050267556 Shuros et al. Dec 2005 A1
20060004323 Chang et al. Jan 2006 A1
20060018949 Ammon et al. Jan 2006 A1
20060024564 Manclaw Feb 2006 A1
20060025765 Landman et al. Feb 2006 A1
20060062786 Salcedo et al. Mar 2006 A1
20060083194 Dhrimaj et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060089638 Carmel et al. Apr 2006 A1
20060095096 DeBenedictis et al. May 2006 A1
20060106375 Werneth et al. May 2006 A1
20060142790 Gertner Jun 2006 A1
20060147492 Hunter et al. Jul 2006 A1
20060167106 Zhang et al. Jul 2006 A1
20060167498 DiLorenzo Jul 2006 A1
20060171895 Bucay-Couto Aug 2006 A1
20060184221 Stewart et al. Aug 2006 A1
20060195139 Gertner Aug 2006 A1
20060206150 Demarais et al. Sep 2006 A1
20060224153 Fischell et al. Oct 2006 A1
20060239921 Mangat et al. Oct 2006 A1
20060240070 Cromack et al. Oct 2006 A1
20060247266 Yamada et al. Nov 2006 A1
20060247760 Ganesan et al. Nov 2006 A1
20060263393 Demopulos et al. Nov 2006 A1
20060269555 Salcedo et al. Nov 2006 A1
20060271111 Demarais et al. Nov 2006 A1
20060287644 Inganas et al. Dec 2006 A1
20070016184 Cropper et al. Jan 2007 A1
20070016274 Boveja et al. Jan 2007 A1
20070027390 Maschke et al. Feb 2007 A1
20070043077 Mewshaw et al. Feb 2007 A1
20070043409 Brian et al. Feb 2007 A1
20070049924 Rahn Mar 2007 A1
20070066972 Ormsby et al. Mar 2007 A1
20070073151 Lee Mar 2007 A1
20070093710 Maschke Apr 2007 A1
20070100405 Thompson et al. May 2007 A1
20070106247 Burnett et al. May 2007 A1
20070112327 Yun et al. May 2007 A1
20070118107 Francischelli et al. May 2007 A1
20070129760 Demarais et al. Jun 2007 A1
20070129761 Demarais et al. Jun 2007 A1
20070135875 Demarais et al. Jun 2007 A1
20070149963 Matsukuma et al. Jun 2007 A1
20070162109 Davila et al. Jul 2007 A1
20070173805 Weinberg et al. Jul 2007 A1
20070179496 Swoyer et al. Aug 2007 A1
20070203480 Mody et al. Aug 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070208134 Hunter et al. Sep 2007 A1
20070208210 Gelfand et al. Sep 2007 A1
20070208256 Marilla Sep 2007 A1
20070208301 Evard et al. Sep 2007 A1
20070219576 Cangialosi Sep 2007 A1
20070225781 Saadat et al. Sep 2007 A1
20070233170 Gertner Oct 2007 A1
20070239062 Chopra et al. Oct 2007 A1
20070248639 Demopulos et al. Oct 2007 A1
20070249703 Mewshaw et al. Oct 2007 A1
20070254833 Hunter et al. Nov 2007 A1
20070265687 Deem et al. Nov 2007 A1
20070278103 Hoerr et al. Dec 2007 A1
20070282302 Wachsman et al. Dec 2007 A1
20070292411 Salcedo et al. Dec 2007 A1
20070293782 Marino Dec 2007 A1
20070299043 Hunter et al. Dec 2007 A1
20080004673 Rossing et al. Jan 2008 A1
20080009927 Vilims Jan 2008 A1
20080015501 Gertner Jan 2008 A1
20080021408 Jacobsen et al. Jan 2008 A1
20080033049 Mewshaw Feb 2008 A1
20080039746 Hissong et al. Feb 2008 A1
20080039830 Munger et al. Feb 2008 A1
20080051454 Wang Feb 2008 A1
20080064957 Spence Mar 2008 A1
20080071269 Hilario et al. Mar 2008 A1
20080071306 Gertner Mar 2008 A1
20080082109 Moll et al. Apr 2008 A1
20080086072 Bonutti et al. Apr 2008 A1
20080091193 Kauphusman et al. Apr 2008 A1
20080097251 Babaev Apr 2008 A1
20080097426 Root et al. Apr 2008 A1
20080108867 Zhou May 2008 A1
20080119879 Brenneman et al. May 2008 A1
20080125772 Stone et al. May 2008 A1
20080132450 Lee et al. Jun 2008 A1
20080140002 Ramzipoor et al. Jun 2008 A1
20080147002 Gertner Jun 2008 A1
20080161662 Golijanin et al. Jul 2008 A1
20080161717 Gertner Jul 2008 A1
20080161801 Steinke et al. Jul 2008 A1
20080171974 Lafontaine et al. Jul 2008 A1
20080172035 Starksen et al. Jul 2008 A1
20080172104 Kieval et al. Jul 2008 A1
20080188912 Stone et al. Aug 2008 A1
20080188913 Stone et al. Aug 2008 A1
20080208162 Joshi Aug 2008 A1
20080208169 Boyle et al. Aug 2008 A1
20080213331 Gelfand et al. Sep 2008 A1
20080215117 Gross Sep 2008 A1
20080221448 Khuri-Yakub et al. Sep 2008 A1
20080234790 Bayer et al. Sep 2008 A1
20080243091 Humphreys et al. Oct 2008 A1
20080245371 Gruber Oct 2008 A1
20080249525 Lee et al. Oct 2008 A1
20080249547 Dunn Oct 2008 A1
20080255550 Bell Oct 2008 A1
20080255642 Zarins et al. Oct 2008 A1
20080262489 Steinke Oct 2008 A1
20080275484 Gertner Nov 2008 A1
20080281312 Werneth et al. Nov 2008 A1
20080281347 Gertner Nov 2008 A1
20080287918 Rosenman et al. Nov 2008 A1
20080294037 Richter Nov 2008 A1
20080300618 Gertner Dec 2008 A1
20080312644 Fourkas et al. Dec 2008 A1
20080312673 Viswanathan et al. Dec 2008 A1
20080317818 Griffith et al. Dec 2008 A1
20090018486 Goren et al. Jan 2009 A1
20090018609 DiLorenzo Jan 2009 A1
20090024194 Arcot-Krishnamurthy et al. Jan 2009 A1
20090030312 Hadjicostis Jan 2009 A1
20090036948 Levin et al. Feb 2009 A1
20090043372 Northrop et al. Feb 2009 A1
20090054082 Kim et al. Feb 2009 A1
20090062873 Wu et al. Mar 2009 A1
20090069671 Anderson Mar 2009 A1
20090076409 Wu et al. Mar 2009 A1
20090088735 Abboud et al. Apr 2009 A1
20090105631 Kieval Apr 2009 A1
20090112202 Young Apr 2009 A1
20090118620 Tgavalekos et al. May 2009 A1
20090118726 Auth et al. May 2009 A1
20090125099 Weber et al. May 2009 A1
20090131798 Minar et al. May 2009 A1
20090143640 Saadat et al. Jun 2009 A1
20090156988 Ferren et al. Jun 2009 A1
20090157057 Ferren et al. Jun 2009 A1
20090157161 Desai et al. Jun 2009 A1
20090171333 Hon Jul 2009 A1
20090192558 Whitehurst et al. Jul 2009 A1
20090198223 Thilwind et al. Aug 2009 A1
20090203962 Miller et al. Aug 2009 A1
20090203993 Mangat et al. Aug 2009 A1
20090204170 Hastings et al. Aug 2009 A1
20090210953 Moyer et al. Aug 2009 A1
20090216317 Cromack et al. Aug 2009 A1
20090221955 Babaev Sep 2009 A1
20090226429 Salcedo et al. Sep 2009 A1
20090240249 Chan et al. Sep 2009 A1
20090247933 Maor et al. Oct 2009 A1
20090247966 Gunn et al. Oct 2009 A1
20090248012 Maor et al. Oct 2009 A1
20090253974 Rahme Oct 2009 A1
20090264755 Chen et al. Oct 2009 A1
20090270850 Zhou et al. Oct 2009 A1
20090281533 Ingle et al. Nov 2009 A1
20090287137 Crowley Nov 2009 A1
20090318749 Stolen et al. Dec 2009 A1
20100009267 Chase et al. Jan 2010 A1
20100030061 Canfield et al. Feb 2010 A1
20100048983 Ball et al. Feb 2010 A1
20100049099 Thapliyal et al. Feb 2010 A1
20100049186 Ingle et al. Feb 2010 A1
20100049188 Nelson et al. Feb 2010 A1
20100049191 Habib et al. Feb 2010 A1
20100049283 Johnson Feb 2010 A1
20100069837 Rassat et al. Mar 2010 A1
20100076299 Gustus et al. Mar 2010 A1
20100076425 Carroux Mar 2010 A1
20100087782 Ghaffari et al. Apr 2010 A1
20100106005 Karczmar et al. Apr 2010 A1
20100114244 Manda et al. May 2010 A1
20100130836 Malchano et al. May 2010 A1
20100137860 Demarais et al. Jun 2010 A1
20100137952 Demarais et al. Jun 2010 A1
20100160903 Krespi Jun 2010 A1
20100160906 Jarrard Jun 2010 A1
20100168624 Sliwa Jul 2010 A1
20100168731 Wu et al. Jul 2010 A1
20100168739 Wu et al. Jul 2010 A1
20100174282 Demarais et al. Jul 2010 A1
20100191112 Demarais et al. Jul 2010 A1
20100191232 Boveda Jul 2010 A1
20100217162 Hissong et al. Aug 2010 A1
20100222786 Kassab Sep 2010 A1
20100222851 Deem et al. Sep 2010 A1
20100222854 Demarais et al. Sep 2010 A1
20100228122 Keenan et al. Sep 2010 A1
20100249604 Hastings et al. Sep 2010 A1
20100249773 Clark et al. Sep 2010 A1
20100256616 Katoh et al. Oct 2010 A1
20100268217 Habib Oct 2010 A1
20100268307 Demarais et al. Oct 2010 A1
20100284927 Lu et al. Nov 2010 A1
20100286684 Hata et al. Nov 2010 A1
20100298821 Garbagnati Nov 2010 A1
20100305036 Barnes et al. Dec 2010 A1
20100312141 Keast et al. Dec 2010 A1
20100324472 Wulfman Dec 2010 A1
20110009750 Taylor et al. Jan 2011 A1
20110021976 Li et al. Jan 2011 A1
20110034832 Cioanta et al. Feb 2011 A1
20110040324 McCarthy et al. Feb 2011 A1
20110044942 Puri et al. Feb 2011 A1
20110060324 Wu et al. Mar 2011 A1
20110071400 Hastings et al. Mar 2011 A1
20110071401 Hastings et al. Mar 2011 A1
20110077498 McDaniel Mar 2011 A1
20110092781 Gertner Apr 2011 A1
20110092880 Gertner Apr 2011 A1
20110104061 Seward May 2011 A1
20110112400 Emery et al. May 2011 A1
20110118600 Gertner May 2011 A1
20110118726 De La Rama et al. May 2011 A1
20110130708 Perry et al. Jun 2011 A1
20110137155 Weber et al. Jun 2011 A1
20110144479 Hastings et al. Jun 2011 A1
20110146673 Keast et al. Jun 2011 A1
20110166499 Demarais et al. Jul 2011 A1
20110178570 Demarais Jul 2011 A1
20110200171 Beetel et al. Aug 2011 A1
20110202098 Demarais et al. Aug 2011 A1
20110207758 Sobotka et al. Aug 2011 A1
20110208096 Demarais et al. Aug 2011 A1
20110257523 Hastings et al. Oct 2011 A1
20110257564 Demarais et al. Oct 2011 A1
20110257622 Salahieh et al. Oct 2011 A1
20110257641 Hastings et al. Oct 2011 A1
20110257642 Griggs, III Oct 2011 A1
20110263921 Vrba et al. Oct 2011 A1
20110264011 Wu et al. Oct 2011 A1
20110264075 Leung et al. Oct 2011 A1
20110264086 Ingle Oct 2011 A1
20110264116 Kocur et al. Oct 2011 A1
20110270238 Rizq et al. Nov 2011 A1
20110306851 Wang Dec 2011 A1
20110319809 Smith Dec 2011 A1
20120029496 Smith Feb 2012 A1
20120029500 Jenson Feb 2012 A1
20120029505 Jenson Feb 2012 A1
20120029509 Smith Feb 2012 A1
20120029510 Haverkost Feb 2012 A1
20120029511 Smith Feb 2012 A1
20120029512 Willard et al. Feb 2012 A1
20120029513 Smith et al. Feb 2012 A1
20120059241 Hastings et al. Mar 2012 A1
20120059286 Hastings et al. Mar 2012 A1
20120065506 Smith Mar 2012 A1
20120065554 Pikus Mar 2012 A1
20120095461 Herscher et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120101490 Smith Apr 2012 A1
20120101538 Ballakur et al. Apr 2012 A1
20120109021 Hastings et al. May 2012 A1
20120116382 Ku et al. May 2012 A1
20120116383 Mauch et al. May 2012 A1
20120116392 Willard May 2012 A1
20120116438 Salahieh et al. May 2012 A1
20120116486 Naga et al. May 2012 A1
20120123243 Hastings May 2012 A1
20120123258 Willard May 2012 A1
20120123261 Jenson et al. May 2012 A1
20120123303 Sogard et al. May 2012 A1
20120123406 Edmunds et al. May 2012 A1
20120130289 Demarais et al. May 2012 A1
20120130345 Levin et al. May 2012 A1
20120130359 Turovskiy May 2012 A1
20120130360 Buckley et al. May 2012 A1
20120130362 Hastings et al. May 2012 A1
20120130368 Jenson May 2012 A1
20120130458 Ryba et al. May 2012 A1
20120136344 Buckley et al. May 2012 A1
20120136349 Hastings May 2012 A1
20120136350 Goshgarian et al. May 2012 A1
20120136417 Buckley et al. May 2012 A1
20120136418 Buckley et al. May 2012 A1
20120143181 Demarais et al. Jun 2012 A1
20120143293 Mauch et al. Jun 2012 A1
20120143294 Clark et al. Jun 2012 A1
20120150267 Buckley et al. Jun 2012 A1
20120157986 Stone et al. Jun 2012 A1
20120157987 Steinke et al. Jun 2012 A1
20120157988 Stone et al. Jun 2012 A1
20120157989 Stone et al. Jun 2012 A1
20120157992 Smith et al. Jun 2012 A1
20120157993 Jenson et al. Jun 2012 A1
20120158101 Stone et al. Jun 2012 A1
20120158104 Huynh et al. Jun 2012 A1
20120172837 Demarais et al. Jul 2012 A1
20120172870 Jenson et al. Jul 2012 A1
20120184952 Jenson et al. Jul 2012 A1
20120197198 Demarais et al. Aug 2012 A1
20120197252 Deem et al. Aug 2012 A1
20120232409 Stahmann et al. Sep 2012 A1
20120265066 Crow et al. Oct 2012 A1
20120265198 Crow et al. Oct 2012 A1
20130012844 Demarais et al. Jan 2013 A1
20130012866 Deem et al. Jan 2013 A1
20130012867 Demarais et al. Jan 2013 A1
20130013024 Levin et al. Jan 2013 A1
20130023865 Steinke et al. Jan 2013 A1
20130035681 Subramaniam et al. Feb 2013 A1
20130066316 Steinke et al. Mar 2013 A1
20130085489 Fain et al. Apr 2013 A1
20130090563 Weber Apr 2013 A1
20130090578 Smith et al. Apr 2013 A1
20130090647 Smith Apr 2013 A1
20130090649 Smith et al. Apr 2013 A1
20130090650 Jenson et al. Apr 2013 A1
20130090651 Smith Apr 2013 A1
20130090652 Jenson Apr 2013 A1
20130096550 Hill Apr 2013 A1
20130096553 Hill et al. Apr 2013 A1
20130096554 Groff et al. Apr 2013 A1
20130096604 Hanson et al. Apr 2013 A1
20130110106 Richardson May 2013 A1
20130116687 Willard May 2013 A1
20130165764 Scheuermann et al. Jun 2013 A1
20130165844 Shuros et al. Jun 2013 A1
20130165916 Mathur et al. Jun 2013 A1
20130165917 Mathur et al. Jun 2013 A1
20130165920 Weber et al. Jun 2013 A1
20130165923 Mathur et al. Jun 2013 A1
20130165924 Mathur et al. Jun 2013 A1
20130165925 Mathur et al. Jun 2013 A1
20130165926 Mathur et al. Jun 2013 A1
20130165990 Mathur et al. Jun 2013 A1
20130172815 Perry et al. Jul 2013 A1
20130172872 Subramaniam et al. Jul 2013 A1
20130172877 Subramaniam et al. Jul 2013 A1
20130172878 Smith Jul 2013 A1
20130172879 Sutermeister Jul 2013 A1
20130172880 Willard Jul 2013 A1
20130172881 Hill et al. Jul 2013 A1
Foreign Referenced Citations (41)
Number Date Country
10038737 Feb 2002 DE
1053720 Nov 2000 EP
1180004 Feb 2002 EP
1335677 Aug 2003 EP
1874211 Jan 2008 EP
1906853 Apr 2008 EP
1961394 Aug 2008 EP
1620156 Jul 2009 EP
2076193 Jul 2009 EP
2091455 Aug 2009 EP
2197533 Jun 2010 EP
2208506 Jul 2010 EP
1579889 Aug 2010 EP
2092957 Jan 2011 EP
2349044 Aug 2011 EP
2027882 Oct 2011 EP
2378956 Oct 2011 EP
2037840 Dec 2011 EP
2204134 Apr 2012 EP
2320821 Oct 2012 EP
2456301 Jul 2009 GB
9858588 Dec 1998 WO
9900060 Jan 1999 WO
0042934 Jul 2000 WO
0047118 Aug 2000 WO
03026525 Apr 2003 WO
2004100813 Nov 2004 WO
2004110258 Dec 2004 WO
2006105121 Oct 2006 WO
2008014465 Jan 2008 WO
2009121017 Oct 2009 WO
2010067360 Jun 2010 WO
2010102310 Sep 2010 WO
2011005901 Jan 2011 WO
2011053757 May 2011 WO
2011053772 May 2011 WO
2011082279 Jul 2011 WO
2011091069 Jul 2011 WO
2011130534 Oct 2011 WO
2012019156 Feb 2012 WO
2013049601 Apr 2013 WO
Non-Patent Literature Citations (68)
Entry
US 8,398,630, 03/2013, Demarais et al. (withdrawn).
Van Den Berg, “Light echoes image the human body,” OLE, Oct. 2001, p. 35-37.
“IntraLuminal: Products,” IntraLuminal Therapeutics, Inc., 2003, p. 1-9.
“Laser Catheter to Aid Coronary Surgery,” TechTalk: MIT, Jan. 9, 1991, p. 1-4.
“Optical Coherence Tomography: Advantages of OCT,” LightLab Imaging Technology.
“Optical Coherence Tomography: Image Gallery Cardiovascular Procedures,” LightLab Imaging Technology.
“Optical Coherence Tomography: LightLab Imaging Starts US Cardiology Clinical Investigations,” LightLab Imaging Technology, 2002.
“Optical Coherence Tomography: LightLab Sees Bright Prospects for Cardiac Application of OCT Technology,” LightLab Imaging Technology, 2001, vol. 27, No. 35.
“Optical Coherence Tomography: What is OCT?,” LightLab Imaging Technology.
“Optical Coherence Tomography: Why Use OCT?,” LightLab Imaging Technology.
“Products—Functional Measurement,” VOLCANO Functional Measurement Products US, Mar. 24, 2003, p. 1-2.
Brown et al., “Radiofrequency capacitive heaters: the effect of coupling medium resistivity on power absorption along a mouse leg,” Physics in Medicine and Biology, 1993, p. 1-12, vol. 38.
Carrington, “Future of CVI: It's all about plaque: Identification of vulnerable lesions, not ‘rusty pipes,’ could become cornerstone of preventive cardiology,” Diagnostic Imaging, 2001, p. 1-8.
Chen et al., “Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo,” EuroIntervention, 2013, p. 1-8.
Cimino, “Preventing plaque attack,” Mass High Tech, 2001, p. 1-2.
Dahm et al., “Relation of Degree of Laser Debulking of In-Stent Restenosis as a Predictor of Restenosis Rate,” The American Journal of Cardiology, 2002, p. 68-70, vol. 90.
De Korte et al., “Characterization of Plaque Components With Intravascular Ultrasound Elastography in Human Femoral and Coronary Arteries In Vitro,” Circulation, Aug. 8, 2000, p. 617-623.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook,” Oct. 1986, p. 1-2, Fourth Edition.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook: Contents,” Oct. 1986, p. 1-5, Fourth Edition.
Fournier-Desseux et al., “Assessment of 1-lead and 2-lead electrode patterns in electrical impedance endotomography,” Physiological Measurement, 2005, p. 337-349. Vo. 26, Institute of Physics Publishing.
Fram et al., “Feasibility of Radiofrequency Powered, Thermal Balloon Ablation of Atrioventricular Bypass Tracts Via the Coronary Sinus: In Vivo Canine Studies,” PACE, Aug. 1995, p. 1518-1530, vol. 18.
Fram et al., “Low Pressure Radiofrequency Balloon Angioplasty: Evaluation in Porcine Peripheral Arteries,” JACC, 1993, p. 1512-1521, vol. 21, No. 6, American College of Cardiology.
Fujimori et al., “Significant Prevention of In-Stent Restenosis by Evans Blue in Patients with Acute Myocardial Infarction,” American Heart Association, 2002.
Fujita et al., “Sarpogrelate, An Antagonist of 5-HT(2A) Receptor, Treatment Reduces Restenosis After Coronary Stenting,” American Heart Association, 2002.
Gabriel, “Appendix A: Experimental Data,” 1999, p. 1-21.
Gabriel, “Appendix C: Modeling the frequency dependence of the dielectric properties to a 4 dispersions spectrum,” p. 1-6.
Gregory et al., “Liquid Core Light Guide for Laser Angioplasty,” The Journal of Quantum Electronics, Dec. 1990, p. 2289-2296, vol. 26, No. 12.
Kaplan et al., “Healing after Arterial Dilatation with Radiofrequency Thermal and Nonthermal Balloon Angioplasty Sytems,” Journal of Investigative Surgery, 1993, p. 33-52, vol. 6.
Kolata, “New Studies Question Value of Opening Arteries,” The New York Times, Mar. 21, 2004, p. 1-5.
Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, Aug. 1997, p. 439-446, vol. 16, No. 4.
Kurtz et al., “Lamellar Refractive Surgery with Scanned Intrastromal Picosecond and Femtosecond Laser Pulses in Animal Eyes,” Journal of Refractive Surgery, Sep./Oct. 1998, p. 541-548.
Lee et al., “Thermal Compression and Molding of Atherosclerotic Vascular Tissue With Use of Radiofrequency Energy: Implications for Radiofrequency Balloon Angioplasty,” JACC, 1989, p. 1167-1175, vol. 13, No. 5, American College of Cardiology.
Lima et al., “Efficacy and Safety of Oral Sirolimus to Treat and Prevent In-Stent Restenosis: A Pilot Study Results,” American Heart Association, 2002, p. 2929.
Lima et al., “Systemic Immunosuppression Inhibits In-Stent Coronary Intimal Proliferation in Renal Transplant Patients,” American Heart Association, 2002, p. 2928.
Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization,” The New England Journal of Medicine, Jun. 6, 2012, p. 1773-1780, vol. 346, No. 23.
Muller-Leisse et al., “Effectiveness and Safety of Ultrasonic Atherosclerotic Plaque Ablation: In Vitro Investigation,” CardioVascular and Interventional Radiology, 1993, p. 303-307, vol. 16.
Nair et al., “Regularized Autoregressive Analysis of Intravascular Ultrasound Backscatter: Improvement in Spatial Accuracy of Tissue Maps,” IEEE Transactions on Ultrasonics, Apr. 2004, p. 420-431, vol. 51, No. 4.
Popma et al., “Percutaneous Coronary and Valvular Intervention,” p. 1364-1405.
Resar et al., “Endoluminal Sealing of Vascular Wall Disruptions With Radiofrequency-Heated Balloon Angioplasty,” Catheterization and Cardiovascular Diagnosis, 1993, p. 161-167, vol. 29.
Romer et al., “Histopathology of Human Coronary Atherosclerosis by Quantifying Its Chemical Composition With Raman Spectroscopy,” Circulation, 1998, p. 878-885, vol. 97.
Schauerte et al., “Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation,” Circulation, 2000, p. 2774-2780, vol. 102.
Scheller et al., “Intracoronary Paclitaxel Added to Contrast Media Inhibits In-Stent Restenosis of Porcine Coronary Arteries,” American Heart Association, 2002, p. 2227.
Scheller et al., “Potential solutions to the current problem: coated balloon,” EuroIntervention, 2008, p. C63-C66, vol. 4 (Supplement C).
Shaffer, “Scientific basis of laser energy,” Clinics in Sports Medicine, 2002, p. 585-598, vol. 21.
Shmatukha et al., “MRI temperature mapping during thermal balloon angioplasty,” Physics in Medicine and Biology, 2006, p. N163-N171, vol. 51.
Slager et al., “Vaporization of Atherosclerotic Plaques by Spark Erosion,” J Am Coll Cardiol, 1985, p. 21-25.
Stiles et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEEE Transactions on Biomedical Engineering, Jul. 2003, p. 916-921, vol. 50, No. 7.
Suselbeck et al., “In vivo intravascular electric impedance spectroscopy using a new catheter with integrated microelectrodes,” Basic Res Cardiol, 2005, p. 28-34, vol. 100.
Suselbeck et al., “Intravascular electric impedance spectroscopy of atherosclerotic lesions using a new impedance catheter system,” Basic Res Cardiol, 2005, p. 446-452, vol. 100.
Tepe et al., “Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg,” The New England Journal of Medicine, 2008, p. 689-699, vol. 358.
CardioVascular Technologies Inc., “Heated Balloon Device Technology,” 11 pages, 2008.
Strategic Business Development, Inc., “Thermal and Disruptive Angioplasty: A Physician's Guide,” 8 pages, 1990.
Zhang et al., “Non-contact Radio-Frequency Ablation for Obtaining Deeper Lesions,” IEEE Transaction on Biomedical Engineering, vol. 50, No. 2, 6 pages, Feb. 2003.
Lazebnik et al., “Tissue Strain Analytics Virtual Touch Tissue Imaging and Qualification,” Siemens Whitepaper, Oct. 2008, 7 pages.
Han et al., “Third-Generation Cryosurgery for Primary and Recurrent Prostate Caner,” BJU International, vol. 93, pp. 14-18.
Zhou et al., “Mechanism Research of Cryoanalgesia,” Forefront Publishing Group, 1995.
Florete, “Cryoblative Procedure for Back Pain,” Jacksonville Medicine, Oct. 1998, 10 pages.
Stevenson, “Irrigated RF Ablation: Power Titration and Fluid Management for Optimal Safety Efficacy,” 2005, 4 pages.
Giliatt et al., “The Cause of Nerve Damage in Acute Compression,” Trans Am Neurol Assoc, 1974: 99; 71-4.
Omura et al., “A Mild Acute Compression Induces Neurapraxia in Rat Sciatic Nerve,” The International Journal of Neuroscience, vol. 114 (12), pp. 1561-1572.
Baun, “Interaction with Soft Tissue,” Principles of General & Vascular Sonography, Chapter 2, pp. 23-24, Before Mar. 2012.
Blue Cross Blue Shield Medicaly Policy, “Surgery Section—MRI-Guided Focused Ultrasound (MRgFUS) for the Treatment of Uterine Fibroids and Other Tumors,” 2005, 5 pages.
Gentry et al., “Combines 3D Intracardiac Echo and Ultrasound Ablation,” Medical Imaging 2003: Ultrasonic and Signal Processing, vol. 5035, 2003, pp. 166-173.
Lafon et al., “Optmizing the Shape of Ultrasound Transducers for Interstitial Thermal Ablations,” MEd Phys. Mar. 2002; 29(3): 290-7 (abstract only).
G. Ter Haar, “Ultrasound Focal Beam Surgery,” Ultrasound in Med. & Biol., 1995, vol. 21, No. 9, pp. 1089-1100.
Seip et al., “Transurethral High Intensity Focused Ultrasound: Catheter Based Prototypes and Experimental Results,” IEEE Ultrasonics Symposium Proceeding, 2000, 4 pages.
Toytman et al., “Tissue Dissection with Ultrafast Laser Using Extended and Multiple Foci,” SPIE Proceeding, Optical Interactions with Tissues and Cells XXI, vol. 7562, 2010, 10 pages.
Zhoue et al., “Non-Thermal Ablation of Rabbit Liver VX2 Tumore by Pulsed High Intensity Focused Ultrasound Contrast Agent: Pathological Characteristics,” World Journal of Gastroenterology, vol. 14(43), Nov. 21, 2008, pp. 6743-6747.
Related Publications (1)
Number Date Country
20130172872 A1 Jul 2013 US
Provisional Applications (3)
Number Date Country
61580972 Dec 2011 US
61605615 Mar 2012 US
61605624 Mar 2012 US